Clinical Database
Over 500 indications in Phase 2,3 or NDA development. Updated daily, includes PRs and live share price.
| Ticker | Price | Drug | Indication | Stage | Link | Updated |
|---|---|---|---|---|---|---|
| ABIO | 0.43 | Gencaro | Chronic Heart Failure | Phase 3 | Initiate Phase 3 pending funding. Able to initiate 6mths following funding | 12/16/2011 |
| ACAD | 1.42 | Pimavanserin | Alzheimer's | Phase 2 | Progress halted | 10/28/2010 |
| ACAD | 1.42 | Pimavanserin | Schizophrenia | Phase 3 | Progress halted | 10/28/2010 |
| ACAD | 1.42 | AGN-XX/YY | Chronic pain | Phase 2 | Ongoing | 08/20/2011 |
| ACAD | 1.42 | Pimavanserin | Parkinson's Disease | Phase 3 | Aim to complete 2H 2012 | 05/09/2012 |
| ACHN | 6.50 | ACH-1625 | HCV Hepatitis C | Phase 2 | Phase 2 data released April 2012 | 04/24/2012 |
| ACHN | 6.50 | Elvucitabine | HIV | Phase 2 | Seeking partner to advance | 07/31/2010 |
| ACHN | 6.50 | ACH-2928 | HCV Hepatitis C | Phase 1b | Phase 1b data released Dec 2011 | 12/06/2011 |
| ACRX | 3.60 | ARX-01 | Post-operative pain following open abdominal surgery | Phase 3 | Phase 3 initiated March 2012. Topline data are due 2H 2012. Second Phase 3 initiated April 2012. Data also due 2H 2012. Third Phase 3 trial to be initiated later in 2012 with data due late 2012/early2013 | 05/09/2012 |
| ACRX | 3.60 | ARX-02 | Cancer breakthrough pain | Phase 2 | Further development halted until funding secured | 04/19/2012 |
| ACRX | 3.60 | ARX-03 | Mild sedation and pain relief | Phase 2 | Further development halted until funding secured | 04/19/2012 |
| ACUR | 2.64 | OXECTA | Pain relief | Approved | Approved Jun 17, 2011 | 06/20/2011 |
| ACUR | 2.64 | Acurox | Pain relief | CRL | Negative committee vote | 07/31/2010 |
| AEGR | 14.14 | Lomitapide | Homozygous familial hypercholesterolemia (HoFH) | Phase 3 | PDUFA on or about Jan 5 2012 | 05/01/2012 |
| AEGR | 14.14 | Lomitapide | Ffamilial chylomicronemia | Phase 3 | Initiate Phase 3 2H 2011 | 03/16/2011 |
| AEZS | 0.46 | AEZS-130 | Adult Growth Deficiency | Phase 3 | SPA granted, meet with FDA followed by NDA filing sometime 2012 | 03/28/2012 |
| AEZS | 0.46 | AEZS-130 | Cancer cachexia | Phase 2 | Phase 2 initiated Mar 2012 | 03/09/2012 |
| AEZS | 0.46 | Perifosine | Cancer - Colorectal | Phase 3 | Primary endpoint not met | 04/03/2012 |
| AEZS | 0.46 | AEZS-108 | Cancer - Bladder | Phase 1/2 | Initiated | 12/14/2010 |
| AEZS | 0.46 | AEZS-108 | Cancer - Endometrial | Phase 2 | Intend to initiate Phase 3 trial in 2012 | 03/28/2012 |
| AEZS | 0.46 | Perifosine | Cancer - Myeloma | Phase 3 | Stated that it intends to continue development. License rights returned from KERX | 05/08/2012 |
| AEZS | 0.46 | Perifosine | Cancer - Kidney | Phase 2 | Data presented Sept 2009 | 07/31/2010 |
| AEZS | 0.46 | AEZS-108 | Cancer - Ovarian | Phase 2 | Final data late 2010 | 07/31/2010 |
| AFFY | 13.06 | Peginesatide | Anemia in chronic renal failure (CRF) | Approved | PDUFA Mar 27 2012 - APPROVED | 03/28/2012 |
| AFFY | 13.06 | Peginesatide | Hemodialysis | Phase 2 | Completed | 12/22/2010 |
| AGEN | 5.45 | G-200 | Cancer - Glioma 2nd line | Phase 2 | Data May 20 2010, ongoing additional | 06/10/2011 |
| AGEN | 5.45 | G-100 | Cancer - Glioma first line | Phase 2 | Enrolling | 08/27/2011 |
| AIS | 2.90 | Anturol | Overactive bladder | Approved | Approved Dec 8 2011 | 12/08/2011 |
| AIS | 2.90 | Libigel | Female sexual dysfunction | Phase 3 | Submit NDA by late 2012 | 08/13/2010 |
| AIS | 2.90 | VIBEX | Rheumatoid arthritis (RA) | Aim to file NDA early 2013 | 05/09/2012 | |
| ALIM | 2.40 | Iluvien | Diabetic macular edema | CRL | CRL Nov 2011, two new trials required. Plans to meet with FDA during 2Q 2012 | 04/02/2012 |
| ALKS | 16.42 | BYDUREON | Diabetes - Type 2 | PDUFA | CRL issued Oct 19, 2010, new PDUFA Jan 28 2011 | 08/20/2011 |
| ALKS | 16.42 | VIVITROL | Opioid dependence | Approved | PDUFA Oct 12 '10, Advisory Panel vote 12-1 in favour | 09/17/2010 |
| ALKS | 16.42 | ALKS 33 | Cocaine addiction | Phase 1/2 | Initiate Ph2a Sept 2011 | 08/27/2011 |
| ALKS | 16.42 | ALKS 37 | Opioid-induced constipation | Phase 2b | Phase 2b initiated, data due mid 2012 | 12/16/2011 |
| ALKS | 16.42 | ALKS 33 | Binge eating disorder | Phase 2 | Data released July 2011, endpoint not met. Likely to discontinue | 07/08/2011 |
| ALKS | 16.42 | ALKS 5461 | Major depressive disorder | Phase 2 | Initiated January 2012,data mid 2013 | 01/04/2012 |
| ALKS | 16.42 | ALKS 9070 | Schizophrenia | Phase 3 | Phase 3 trial initiated Dec 2011, data due 1H 2013 | 12/19/2011 |
| ALNY | 9.91 | ALN-RSV01 | RSV (respiratory syncytial virus) infected adult lung transplant patients | Phase 2b | Enrolment complete, data due mid 2012 | 05/04/2012 |
| ALNY | 9.91 | ALN-TTR02 | Transthyretin-mediated amyloidosis (ATTR) | Phase 2 | Initiate Phase 2 2H 2012 | 05/04/2012 |
| ALNY | 9.91 | ALN-PCS | Severe hypercholesterolemia | Phase 1 | Prelim data released Jan 2012. Further data scheduled for 1H 2012 | 02/10/2012 |
| ALTH | 1.79 | FOLOTYN | Cancer - Peripheral T-cell Lymphoma | Acclerated approval | Received SPA Mar 2011, initiated Ph3 Aug 2011 | 08/19/2011 |
| ALTH | 1.79 | FOLOTYN | Cancer - NSCLC | Phase 2b | Not pursuing Ph3 development | 01/11/2011 |
| ALTH | 1.79 | FOLOTYN | Cancer - NHL 2nd line | Phase 1/2a | Data expected 1H 2012 | 12/16/2011 |
| ALTH | 1.79 | FOLOTYN | Cancer - Lymphoma 2nd line | Phase 2 | Ongoing | 08/27/2011 |
| ALTH | 1.79 | FOLOTYN | Cancer - bladder | Phase 2 | Data expected sometime 2012 | 12/14/2011 |
| ALTH | 1.79 | FOLOTYN | Cancer - Breast | Phase 2 | Data expected sometime 2012 | 12/14/2011 |
| ALXA | 0.38 | Staccato loxapine | Schizophrenia | CRL | CRL ISSUED MAY 3 2012 | 05/04/2012 |
| ALXA | 0.38 | Staccato loxapine | Migraine | Phase 2b | Development under review | 07/27/2010 |
| ALXA | 0.38 | Staccato prochlorperazine | Migraine | Phase 2b | Development under review | 07/27/2010 |
| ALXA | 0.38 | AZ 007 | Insomnia | Phase 1 | Working on technical product development of AZ-007. Had initially hoped to initiate Ph 2 in 2011 | 05/21/2011 |
| AMLN | 26.80 | BYDUREON | Diabetes - Type 2 | PDUFA | CRL issued Oct 19, 2010, new PDUFA Jan 28 2011 | 08/20/2011 |
| AMLN | 26.80 | Pramlintide / metreleptin | Obesity | Phase 2 | Discontinued | 08/07/2011 |
| AMLN | 26.80 | Metreleptin | Lipodystrophy | BLA | Rolling BLA commenced Dec 20, 2010. Final submission filed Apr 3, 2012. Requested priority review | 04/04/2012 |
| AMRN | 10.07 | AMR101 | Elevated triglyceride levels | PDUFA | PDUFA July 26 2012 | 11/26/2011 |
| AMRN | 10.07 | AMR101 | Patients on statin therapy with high triglycerides | Cardiovascular outcomes | Initiation of REDUCE-IT cardiovascular outcomes trial by end of 2012 | 11/30/2011 |
| ANAC | 5.31 | GSK ‘052 | Complicated urinary tract infections (cUTI) | Phase 2b | Phase 2b enrolment halted Feb 2012 due to 'microbiological finding' in cUTI patients | 02/07/2012 |
| ANAC | 5.31 | AN2728 | Mild-to-moderate atopic dermatitis | Phase 2a | Various Phase 2 trials to be initiated in 2012. Phase 3 to be initiated mid 2013 | 05/11/2012 |
| ANAC | 5.31 | AN2728 | Mild-to-moderate plaque-type psoriasis | Phase 2b | Promising Prelim Phase 2b data released Dec 2011. Phase 3 planning on hold | 03/14/2012 |
| ANAC | 5.31 | Tavaborole | Onychomycosis | Phase 3 | Top-line data from the second Phase 3 trial due 1Q 2013. NDA due 1H 2103 | 05/11/2012 |
| ANAC | 5.31 | Tavaborole | Onychomycosis | Phase 3 | Top-line data from the first Phase 3 trial is expected Jan 2013. NDA filing due 1H 2013 | 05/11/2012 |
| ANAC | 5.31 | GSK ‘052 | Complicated intra-abdominal infections (cIAI) | Phase 2b | Phase 2b enrolment halted Feb 2012 due to 'microbiological finding' in cUTI patients | 02/07/2012 |
| ANIK | 13.50 | Monovisc | Osteoarthritis | PMA | Waiting for FDA Advisory Panel | 08/13/2011 |
| ANTH | 1.95 | A-623 Blisibimod | Lupus | Phase 2b | Topline data due 2Q 2012 | 05/04/2012 |
| ANTH | 1.95 | A-001 | Acute chest syndrome | Phase 2 | Complete | 08/20/2011 |
| ANTH | 1.95 | Varespladib - Vista 16 | Acute Coronary Syndromes (ACS) | Phase 3 | Failed Phase 3 efficacy trials | 03/11/2012 |
| ANX | 0.54 | ANX-514 (docetaxel) | Cancer - chemo alternative to Taxotere | FDA rejects, new trial required with possible resubmission in 2014 | 10/26/2011 | |
| ANX | 0.54 | ANX-188 | Sickle cell disease | Phase 3 | Plans Phase 3 by end of 2012 | 05/08/2012 |
| ANX | 0.54 | Exelbine | Cancer - NSCLC | CRL | CRL Aug 2011, bioequivalence study required | 10/04/2011 |
| APPY | 0.56 | AppyScore | Appendicitis - Blood test | 510k clinical trial | Data July - FAIL | 07/31/2010 |
| APPY | 0.56 | AppyScore | Acute appendicitis | Phase 3 | Initiate Pivotal trial mid 2012 | 02/02/2012 |
| APRI | 2.47 | Vitaros | Erectile Dysfunction | Approved in Canada | 06/27/2010 | |
| APRI | 2.47 | MycoVa | Onychomycosis | Phase 3 | Preparing for pre-NDA meeting to request regulatory guidance in EU and US | 04/06/2012 |
| APRI | 2.47 | Femprox | Female sexual arousal disorder | Phase 3 | Preparing second Phase 3 | 04/06/2012 |
| APRI | 2.47 | PrevOnco | Cancer - HCC - liver cancer | Phase 2 | Phase 3 and SPA in discussions with the FDA | 04/06/2012 |
| ARIA | 15.98 | Oral ponatinib | Cancer - chronic myeloid leukemia, acute lymphoblastic leukemia | Phase 3 | NDA filing 3Q 2012 | 05/10/2012 |
| ARIA | 15.98 | Oral ponatinib | Cancer - newly diagnosed chronic myeloid leukemia, acute lymphoblastic leukemia | Phase 3 | Phase 3 to be initiated 3Q 2012 | 05/10/2012 |
| ARIA | 15.98 | Ridaforolimus | Cancer - Sarcoma | PDUFA | NDA accepted Oct 5 2011, MAA filed July 2011. PDUFA June 5 2012. Advisory Committee March 20 2012 voted against approval 13-1 | 03/21/2012 |
| ARIA | 15.98 | Ridaforolimus | Cancer - Endometrial | Phase 2 | Interim data released Oct '10 | 10/25/2010 |
| ARIA | 15.98 | Ridaforolimus | Cancer - Breast,Endometrial, Prostate,Lung | Phase 2 | Ongoing | 07/31/2010 |
| ARIA | 15.98 | AP26113 | Cancer - ALK-positive and EGFR-positive lung cancer | Phase 1/2 | Phase 1 initiated Sept 2011, Phase 2 to be initiated mid 2012 | 05/10/2012 |
| ARNA | 5.52 | Lorcaserin | Obesity | CRL/new PDUFA | PDUFA June 27 2012, Advisory Committee Mtg May 10 2012 18-4-1 in favour | 05/11/2012 |
| ARQL | 5.78 | Tivantinib (ARQ 197) | Cancer - NSCLC | Phase 3 | Phase 3 MARQUEE trial initiated Jan 2011 - SPA approved, complete patient enrollment in 2012 with interim data also due later in 2012 | 03/02/2012 |
| ARQL | 5.78 | Tivantinib (ARQ 197) | Cancer - NSCLC | Phase 3 | Phase 3 ATTENTION trial initiated August 2011 | 04/06/2012 |
| ARQL | 5.78 | Tivantinib (ARQ 197) | Cancer - NSCLC patients with a mutated form of the KRAS gene | Phase 2 | Phase 2 initiated July 2012 | 04/06/2012 |
| ARQL | 5.78 | Tivantinib (ARQ 197) | Cancer - Gastric | Phase 2 | Initiated July 2010, data to be released later in 2012 | 04/06/2012 |
| ARQL | 5.78 | Tivantinib (ARQ 197) | Cancer - hepatocellular carcinoma (HCC) | Phase 2 | Phase 2 met endpoint Jan 2012. Full data later in 2012 | 01/17/2012 |
| ARQL | 5.78 | Tivantinib (ARQ 197) + irinotecan and cetuximab | Cancer - colorectal | Phase 2 | Aim to complete enrolment 2012 | 03/02/2012 |
| ARRY | 3.58 | MEK162 (ARRY-162) | Cancer - MEK inhibitor for cancer | Phase 2 | Various Phase 1 and 2 trials ongoing | 05/01/2012 |
| ARRY | 3.58 | MEK162 (ARRY-162) | Cancer - MEK inhibitor for melanoma | Phase 2 | Phase 2 data due by early 2013 | 05/01/2012 |
| ARRY | 3.58 | Selumetinib (AZD6244) + plus dacarbazine | Cancer - Melanoma | Phase 2 | Phase 2 topline data due 2012 | 05/01/2012 |
| ARRY | 3.58 | Selumetinib (AZD6244) plus docetaxel | Cancer - NSCLC second line non small lung cancer | Phase 2 | Phase 2 data released Sept 2011. Primary endpoint (OS) not met. Secondary endpoints met (PFS ORR). Further data due 2Q 2012 | 05/01/2012 |
| ARRY | 3.58 | Selumetinib compared with Temodar | Cancer - metastatic melanoma of the eye | Phase 2 | Ongoing | 08/20/2011 |
| ARRY | 3.58 | Selumetinib with Camptosa | Cancer - 2nd line colorectal cancer | Phase 2 | Ongoing | 08/20/2011 |
| ARRY | 3.58 | Selumetinib with Nexavar | Cancer - Advanced hepatocellular carcinoma | Phase 2 | Ongoing | 08/20/2011 |
| ARRY | 3.58 | Selumetinib with Nexavar | Cancer - recurrent low-grade serous ovarian | Phase 2 | Data presented Apr 2012 | 04/05/2012 |
| ARRY | 3.58 | ARRY-520 plus dexamethasone | Cancer - Refractory Multiple Myeloma MM | Phase 2 | Further Phase 2 data due by early 2013 | 05/01/2012 |
| ARRY | 3.58 | ARRY 520 and Velcade | Cancer - relapsed and refractory MM | Phase 1b | Phase 1b currently enrolling. Data expected by early 2013 | 05/01/2012 |
| ARRY | 3.58 | AMG 151 (ARRY-403) Glucokinase activator | Type 2 diabetes | Phase 2a | Ongoing | 05/01/2012 |
| ARRY | 3.58 | ARRY 502 | Asthma | Phase 2a | Phase 2 topline data due 1Q 2013. Will seek partner for further development | 05/01/2012 |
| ARRY | 3.58 | ARRY 543 | Cancer - HER2 / EGFR inhibitor for cancer | Phase 2 | Ongoing | 11/01/2011 |
| ARRY | 3.58 | ARRY 797 | Pain relief | Phase 2 | Topline Data due summer 2012 | 05/01/2012 |
| ASTM | 2.01 | ixmyelocel-T | Critical limb ischemia | Phase 2b | Enrolment began May 2012. Phase 3 under SPA Feb 2012. Completion due 2015 | 05/10/2012 |
| ASTM | 2.01 | ixmyelocel-T | Stem cells - Dilated Cardiomyopathy | Phase 2 | Initiate Phase 2b 1H 2012 | 11/08/2011 |
| ASTX | 1.59 | Dacogen | Acute myeloid leukemia (AML). | CRL | CRL issued Mar 6 2012 | 03/07/2012 |
| ASTX | 1.59 | AT13387 | Cancer - | Phase 2 | Initiate proof of concept trials 2H 2012 | 05/01/2012 |
| ASTX | 1.59 | SGI-110 | Cancer - MDS/AML | Phase 2 | Phase 2 data readout due late 2012 | 11/01/2011 |
| ASTX | 1.59 | Amuvatinib | Cancer - Small cell lung cancer | Phase 2 | Data due by early 2013 | 05/01/2012 |
| ASTX | 1.59 | AT7519 | Phase 2 | Data due by early 2013 | 05/01/2012 | |
| ATHX | 1.36 | Multistem | Acute Myocardial Infarction - Heart attacks | Phase 2 | Planning | 08/20/2011 |
| ATHX | 1.36 | Multistem | Ulcerative colitis | Phase 2 | Phase 2 topline data due early 2013 | 05/15/2012 |
| ATHX | 1.36 | Multistem | Ischemic stroke | Phase 2 | Initiated 3Q 2011. Ongoing | 05/15/2012 |
| AVEO | 11.28 | Ficlatuzumab | Cancer - Non-small cell lung cancer (NSCLC) | Phase 2 | Phase 2 prelim data - not statistical significance shown | 05/04/2012 |
| AVEO | 11.28 | Tivozanib | Cancer - colorectal | Phase 2 | Initiated Phase 2 Dec 2011 | 12/22/2011 |
| AVEO | 11.28 | Tivozanib | Cancer - advanced renal cell carcinoma | Phase 3 | Phase 3 Topline data due released Jan 2012. Full data at ASCO 2012. MAA and NDA due to be filed 3Q 2012 | 05/17/2012 |
| AVII | 0.61 | AVII658 eteplirsen | Duchenne muscular dystrophy | Phase 2b | Phase 2b data April 2012. Endpoint met but no improvement in walking | 04/26/2012 |
| AVNR | 2.71 | NUEDEXTA | Pseudobulbar affect | Approved | Approved Oct 30 2010, possibly file MAA under accelerated review by the end of 2011 | 07/26/2011 |
| AVNR | 2.71 | NUEDEXTA | Diabetic peripheral neuropathic pain | Phase 3 | Phase 3 additional trial required | 07/31/2010 |
| AVNR | 2.71 | AVP-923 | Central neuropathic pain in patients with multiple sclerosis | Phase 2 | Phase 2 initiated Nov 2011 | 11/05/2011 |
| BCRX | 3.30 | BCX4208 | Gout | Phase 2b | Phase 3 initiation pending partnership confirmation due by end of 2012 | 05/08/2012 |
| BCRX | 3.30 | BCX4208 | Moderate renal impairment | Phase 2 | Complete enrolment during 3Q 2012 | 05/08/2012 |
| BCRX | 3.30 | Forodesine | Cancer - Chronic lymphocytic leukemia | Phase 2 | Data Dec '10 | 12/03/2010 |
| BCRX | 3.30 | Forodesine | Cancer - Chronic lymphocytic leukemia | Phase 2 | Data Sep '10 | 09/15/2010 |
| BCRX | 3.30 | Peramivir - Study 303 | INFLUENZA ACUTE | Phase 3 | Planned interim analysis of Phase 3 due following end of Southern Hemisphere flu season | 05/08/2012 |
| BCRX | 3.30 | Peramivir - Study 301 | INFLUENZA ACUTE | Phase 3 | Data released Jan 2010 | 01/13/2011 |
| BDSI | 4.01 | BEMA Buprenorphine | Pain - acute and chronic | Phase 3 | Initiated Dec 2010, data mid-late Sep 2011 - FAILED | 10/04/2011 |
| BDSI | 4.01 | BEMA Buprenorphine/Naloxone (BNX) | Opioid dependence | Pivotal | Pivotal pharmacokinetic study due 3Q 2012 with NDA filing 1H 2013. | 05/12/2012 |
| BDSI | 4.01 | BEMA Buprenorphine | Chronic pain | Phase 3 | Plans to initiate Phase 3 trials during 3Q 2012 | 05/12/2012 |
| BIOD | 0.65 | VIAject | Diabetes | CRL | CRL Nov 1 2010 | 11/01/2010 |
| BIOD | 0.65 | BIOD-123 | Diabetes - Type 1 | Phase 1 | Intend to initiate Phase 2 trial 3Q 2012 | 04/17/2012 |
| BIOD | 0.65 | Liquid glucagon | Severe hypoglycemia | NDA filing possible 4Q 2013 / 1Q 2014 | 05/11/2012 | |
| BNVI | 0.03 | Menerba | Hot flashes | Phase 3 | Initiated first of two Phase 3 trials Oct 2011, data due 2Q 2013 | 10/28/2011 |
| BNVI | 0.03 | Bezielle | Cancer - Breast | Phase 1 | Complete | 07/31/2010 |
| BPAX | 0.34 | GVAX | Cancer vaccine - prostate | Phase 2 | Clinical hold lifted by FDA, Phase 2 planning | 06/06/2011 |
| BPAX | 0.34 | GM-CSF | Cancer - Pancreatic cancer vaccine | Phase 2 | Data released Mar 2011 | 03/03/2011 |
| BPAX | 0.34 | LibiGel | Female sexual dysfunction | Phase 3 | Failed Phase 3 efficacy trials | 12/14/2011 |
| BPAX | 0.34 | GVAX | Cancer vaccine - Acute myelogenous leukemia | Phase 2 | Completed | 07/31/2010 |
| BPAX | 0.34 | Bio-T-Gel | Male hypogonadism | PDUFA | Approved 2/14/12 | 02/16/2012 |
| CADX | 2.90 | OFIRMEV | Pain and fever | Approved | Approved Nov 4 '10 | 11/04/2010 |
| CBRX | 0.61 | PROCHIEVE (progesterone gel) | Reduction of risk of preterm birth | CRL | CRL Feb 26 2012 | 02/28/2012 |
| CERS | 3.38 | INTERCEPT | Platelets | Phase 3 | Phase 3 clinical trial completed; seeking FDA concurrence on an additional Phase 3 clinical trial - needs funding | 04/06/2012 |
| CERS | 3.38 | INTERCEPT B123 | Plasma | Phase 3 | Phase 3 clinical trials completed; seeking clarity on clinical pathway with the FDA | 04/06/2012 |
| CHTP | 1.99 | NORTHERA | Neurogenic Orthostatic Hypotension | CRL | CRL Mar 28 2012 - FDA Requests Additional Clinical Efficacy Data. Meeting with FDA scheduled for May 2012. Minutes and CC due around the end of May | 05/02/2012 |
| CHTP | 1.99 | Droxidopa | Chronic Fatigue Syndrome | Phase 2 | Initiated Aug 2010, ongoing | 07/28/2011 |
| CHTP | 1.99 | CH-4051 | Rheumatoid arthritis | Phase 2 | Interim Data released Nov 2011, full data 2Q 2012 | 11/05/2011 |
| CHTP | 1.99 | Droxidopa | Fibromyalgia | Phase 2 | Phase 2 topline data released Dec 2011 | 12/22/2011 |
| CHTP | 1.99 | Droxidopa | ADHD | Phase 2 | Prelim data released July 2011 | 07/26/2011 |
| CLDX | 4.11 | CDX-110 rindopepimut | Cancer- glioblastoma multiforme (GBM) front line | Phase 3 | Initiated Phase 3 Dec 2011 | 12/02/2011 |
| CLDX | 4.11 | CDX-110 (rindopepimut) in combination with Avastin | Cancer- glioblastoma multiforme (GBM) refractory | Phase 2 | Initiated Phase 2 Jan 2012 | 01/04/2012 |
| CLDX | 4.11 | CDX-011 | Cancer - Metastatic breast | Phase 2b | Accrual completed Dec 2011, data to be released May 23 2012 | 05/02/2012 |
| CLDX | 4.11 | CDX-1135 | Dense deposit disease (DDD | Phase 2 | Plans to initiate Phase 2 2H 2012 | 05/04/2012 |
| CLDX | 4.11 | CDX-1307 | Cancer - bladder | Phase 2 | Discontinued | 08/13/2011 |
| CLDX | 4.11 | CDX-1401 | Cancer - Various | Phase 1/2 | Phase 1 portion of trial - data due 2H 2012 | 03/11/2012 |
| CLSN | 1.76 | ThermoDox | Cancer - Hepatocellular carcinoma - liver cancer | Phase 3 | DMSB recommends continue through to final PFS analysis due end of 2012 | 04/24/2012 |
| CLSN | 1.76 | ThermoDox | Cancer - Recurrent Chest Wall Breast | Phase 1/2 Piovtal | DSMB recommends advancement to Phase 2 trials | 06/08/2011 |
| CLSN | 1.76 | ThermoDox | Cancer - colorectal liver metastases (CRLM) | Phase 2 | Initiated Phase 2 Feb 2012 | 02/14/2012 |
| CLVS | 18.49 | CO-101 | Cancer - pancreatic | Phase 3 | Topline Phase 3 data due 4Q 2012 | 05/09/2012 |
| CLVS | 18.49 | CO-1686 | Cancer - NSCLC | Phase 1/2 | Initiated Phase 1/2 trial 1Q 2012 | 05/09/2012 |
| CORT | 3.88 | Corlux - Korlym | Cushing's Syndrome | PDUFA | PDUFA date Feb 17 2012 | 06/30/2011 |
| CORT | 3.88 | Corlux - Korlym | Psychotic depression | Phase 3 | Enrolled more patients during 3Q 2011 | 11/07/2011 |
| CPIX | 6.59 | Acetadote | Acute liver failure | Approved | Approved Jan 13, 2011 | 01/14/2011 |
| CPIX | 6.59 | Acetadote | Non-Acetaminophen Induced Acute Liver Failure | CRL | CRL received Dec 2010. Meeting held with FDA. Evaluating future | 11/05/2011 |
| CPIX | 6.59 | Hepatoren | HRS | Phase 2 | Ongoing | 03/08/2012 |
| CPRX | 0.80 | Vigabatrin | Addiction to cocaine | Phase 2b | Initiated Nov 18 2010, Data - early 1Q 2013 | 04/03/2012 |
| CRIS | 4.47 | GDC-0449 vismodegib | Cancer - Advanced Basal Cell Carcinoma | Approved | Approved Jan 31 2012 | 01/30/2012 |
| CRIS | 4.47 | GDC-0449 vismodegib | Gorlin syndrome | Phase 2 | Interim data presented Apr 2011 | 04/04/2011 |
| CRIS | 4.47 | GDC-0449 vismodegib | Cancer - Operable Nodular BCC | Phase 2 | Ongoing | 11/01/2011 |
| CRIS | 4.47 | Debio 0932 | Cancer - lung | Phase 1/2 | Initiate Phase 1/2 trial 2Q 2012 | 05/09/2012 |
| CRTX | 5.27 | CRTX 080 | Hyponatremia | NDA | PDUFA date Oct 29 2012 | 03/14/2012 |
| CTIC | 0.86 | Pixantrone | Cancer - Non-Hodgkin lymphoma | PDUFA | NDA withdrawn Jan 2012. Plans to resubmit 2012 | 01/30/2012 |
| CTIC | 0.86 | Pixantrone | Cancer - Non-Hodgkin lymphoma | EMA | CHMP conditional recommendation given Feb 17 2012. TBC by EMA | 02/17/2012 |
| CTIC | 0.86 | Pixantrone | Cancer - Relapsed/refractory diffuse large B-cell lymphoma ("DLBCL") | Pivotal | Initiated March 2011 | 07/29/2011 |
| CTIC | 0.86 | Pixantrone | Cancer - breast | Phase 2 | Data due 2012 | 03/11/2012 |
| CTIC | 0.86 | Opaxio | Cancer - Ovarian | Phase 3 | Interim Data due 2013 | 03/11/2012 |
| CTIC | 0.86 | Opaxio | Cancer - Esophageal | Phase 2 | Assessing the viability of Phase 3 | 07/29/2011 |
| CTIC | 0.86 | Opaxio | Cancer - astrocytomas and glioblastomas | Phase 2 | Interim data presented at ASCO 2011, addittional trial initiated Aug 2011 | 08/19/2011 |
| CTIC | 0.86 | Tosedostat | Cancer - relapsed or refractory MDS | Phase 2 | Initiate Phase 3 2H 2012 | 03/11/2012 |
| CUR | 0.91 | Cellular Therapy | Amyotrophic lateral sclerosis (Lou Gehrig's) | Phase 1 | Aim to complete 2012, and file for Phase 2 with FDA during 2012 | 04/01/2012 |
| CUR | 0.91 | NSI-189 | Depression | Phase 1 | Initiate Phase 1b late 2011 | 10/28/2011 |
| CVM | 0.39 | Multikline | Cancer - Head and Neck | Phase 3 | Initiated Dec 2010 | 12/23/2010 |
| CXM | 0.23 | Excellagen | Wound care | Approved | 510(k) approved Oct 10 2011 | 10/11/2011 |
| CXM | 0.23 | Generx | Coronary artery disease | Phase 3 | Initiated Phase 3 Russian trial Mar 2012 | 03/21/2012 |
| CXM | 0.23 | Excellarate | Diabetic foot ulcers | Phase 2b | ||
| CYCC | 0.43 | Seliciclib | Cancer - NSCLC | Phase 2b | Retrospective analysis were insufficient to allow meaningful correlation. | 01/11/2012 |
| CYCC | 0.43 | Sapacitabine | Cancer - Myelodysplastic syndromes | Phase 2 | Updateddata due 2012 | 04/01/2012 |
| CYCC | 0.43 | Sapacitabine | Cancer - Acute myeloid leukemia | Phase 3 | Under SPA. - changed to 2-arm trial from original 3-arm | 11/15/2011 |
| CYCC | 0.43 | Sapacitabine | Cancer - NSCLC | Phase 2 | Enrolment ongoing, updated data due 2012 | 04/01/2012 |
| CYCC | 0.43 | Seliciclib | Cancer - Nasopharyngeal | Phase 2 | Ongoing | 07/31/2010 |
| CYTK | 0.90 | CK-2017357 | Amyotrophic Lateral Sclerosis | Phase 2a | First cohort (Part A) data released Nov 2011 | 12/02/2011 |
| CYTK | 0.90 | CK-2017357 | Amyotrophic Lateral Sclerosis | Phase 2a | Phase 2 multiple-dose trial in patients with ALS who are also receiving riluzole (CY 4024). Data from Part B to be available in 1H 2012 | 03/14/2012 |
| CYTK | 0.90 | CK-2017357 | Amyotrophic Lateral Sclerosis | Phase 2a | Phase II dose-titration trial in patients with ALS (CY 4025). Data available in 1H 2012 | 03/14/2012 |
| CYTK | 0.90 | CK-2017357 | Peripheral artery disease | Phase 2a | Data Ph2a released Jun 2011 | 06/03/2011 |
| CYTK | 0.90 | Omecamtiv mecarbil | Acute heart failure | Phase 2b | Decision regarding progression to the second cohort of the ATOMIC-AHF trial in 2Q 2012 following a review of data from the first cohort | 04/27/2012 |
| CYTK | 0.90 | CK-2017357 | Myasthenia gravis | Phase 2a | Data due 2H 2012 | 04/27/2012 |
| CYTR | 2.96 | Tambarotene | Cancer - non-small-cell lung cancer (NSCLC) | Phase 2b | Data due 2H 2012 | 04/20/2011 |
| CYTR | 2.96 | Bafetinib | Cancer - B-Cell Chronic Lymphocytic Leukemia (B-CLL) | Phase 2 | Phase 2 proof of concept completed. Seeking partner for further development | 04/06/2012 |
| CYTR | 2.96 | INNO-206 | Cancer | Phase 2 | Phase 2 clinical trial with INNO-206 for pancreatic cancer initiated Apr 2012 | 04/27/2012 |
| CYTR | 2.96 | INNO-206 | Cancer - Sarcomas | Phase 2b | Initiated Phase 2b in Dec 2011 | 12/22/2011 |
| CYTR | 2.96 | Tambarotene | Cancer - Acute promyelocytic leukemia | Phase 2 | Ongoing | 04/06/2012 |
| CYTR | 2.96 | Bafetinib | Cancer - B-cell chronic lymphocytic leukemia (B-CLL) | Phase 2 | Phase 2 proof of concept completed. Seeking partner for further development | 04/06/2012 |
| DARA | 0.85 | KRN5500 | Pain - Neuropathic | Phase 2 | Phase 2b start 2H 2011 | 08/19/2011 |
| DCTH | 1.99 | CHEMOSAT system | Cancer - melanoma | RTF | NDA filed Dec 22 2010, refused to file, new NDA filing due August 2012 | 05/09/2012 |
| DCTH | 1.99 | CHEMOSAT system | Cancer - liver | Phase 2 | Data released Aug 2011 | 08/27/2011 |
| DEPO | 5.12 | Serada | Hot flashes | Phase 3 | Data released Oct 2011, missed one primary endpoint. Intends to file NDA 2H 2012 | 05/09/2012 |
| DEPO | 5.12 | DM-1796 | Postherpetic neuralgia - shingles | Approved | Approved Jan 28 2011 | 01/30/2011 |
| DEPO | 5.12 | DM-1992 | Parkinson's disease | Phase 2 | Phase 2 initiated Nov 2011 | 01/26/2012 |
| DNDN | 7.27 | PROVENGE | Cancer - castrate-resistant (hormone-refractory) prostate cancer | Approved | Approved 2010 | 04/18/2012 |
| DNDN | 7.27 | PROVENGE Clinical Trial P10-2 | Sequencing of PROVENGE and androgen deprivation therapy (“ADT”) | Phase 2 ongoing | Initiated Phase 2 Aug 2011 | 04/18/2012 |
| DNDN | 7.27 | PROVENGE Clinical Trial P11-3. | PROVENGE with concurrent versus sequential administration of abiraterone acetate plus prednisone in men with metastatic castrate-resistant prostate cancer. | Phase 2 ongoing | Phase 2 initiated Dec 2011 | 04/18/2012 |
| DNDN | 7.27 | DN24-02 | Cancer - high risk HER2+ urothelial carcinoma following surgical resection | Phase 2 | Phase 2 initiated June 2011 | 04/18/2012 |
| DRRX | 0.76 | Eladur | Chronic back pain | Phase 2b | Data released April 2011. FAIL | 04/12/2011 |
| DRRX | 0.76 | Remoxy | Chronic pain | CRL | CRL Jun 23, 2011. Will conduct two bioavailability studies in 2Q 2012 and then meet with the FDA during 3Q 2012 | 05/04/2012 |
| DRXX | 0.76 | Posidur | Post operative pain | Phase 3 | Failed to meet endpoints Jan 2012 in Phase 3 trial. Intends to meet with FDA during summer 2012 with possible late 2012 NDA filing | 05/04/2012 |
| DSCO | 2.38 | Surfaxin | Respiratory Distress Syndrome - Severe | Approved | Approved Mar 6 2012 | 03/07/2012 |
| DSCO | 2.38 | Surfaxin LS | Neonatal RDS | Phase 2 | Talks with FDA regarding further development | 04/06/2012 |
| DSCO | 2.38 | Aerosurg | Respiratory Distress Syndrome - Moderate | Phase 2a | Completed Phase 2. Plan to meet 2H 2011 with FDA regarding further development | 08/19/2011 |
| DSCO | 2.38 | Aerosolized KL4 Sufactant | Patients requiring ventilatory support | Phase 2a | Plans to seek market authorization for the initial AFECTAIR product in the U.S. in the fourth quarter of 2011, and in the EU in the first half of 2012. | 08/19/2011 |
| DVAX | 3.59 | HEPLISAV | Hepatitis B | NDA | Filed BLA Apr 26 2012 in healthy adults. sNDA for patients with chronic kidney disease will be filed if the initial BLA is approved | 04/27/2012 |
| DYAX | 1.61 | Ecallantide | ACE Inhibitor-Induced Angioedema | Phase 2 | Initiated Aug 2011, data expected 2H 2012 | 02/23/2012 |
| ECYT | 6.35 | EC145 | Cancer - ovarian | Phase 3 | Phase 3 PFS data due 1H 2014 | 04/07/2012 |
| ECYT | 6.35 | EC145 | Cancer - NSCLC | Phase 2 | Intends to initiate Phase 2 2Q 2012. Final PFS data is expected to be available by early 2014 | 04/07/2012 |
| ENMD | 1.94 | ENMD-2076 | Cancer - Ovarian | Phase 2 | Phase 2 final data released Oct 2011 | 10/05/2011 |
| ENMD | 1.94 | MKC-1 | Cancer - NSCLC | Phase 2 | Need funding to continue | |
| ENMD | 1.94 | MKC-1 | Cancer - Breast | Phase 2 | Need funding to continue | |
| ENMD | 1.94 | MKC-1 | Cancer - Pancreatic | Phase 2 | Need funding to continue | |
| ENZN | 6.02 | PEG-SN38 | Cancer - breast | Phase 2 | Enrolment completed 3Q 2011 | 10/29/2011 |
| ENZN | 6.02 | PEG-SN38 | Cancer - Colorectal | Phase 2 | Discontinued May 2011 | 08/29/2011 |
| EPCT | 0.19 | Crolibulin | Cancer - Anaplastic thyroid cancer (ATC) | Phase 2 | Initiate Phase 2 1H 2012 | 03/01/2012 |
| EPCT | 0.19 | Ceplene | Cancer - Acute myeloid leukemia AML | Phase 3 | FDA fails to file NDA 2010, New Ph3 trial req'd under SPA. But no intention to proceed with Phase 3 trial due to cost | 04/07/2012 |
| EPCT | 0.19 | NP-1 AmiKet | Pain - DPN, PHN, CPN | Phase 3 | Phase 3 pending | 04/07/2012 |
| EXAS | 9.88 | Cologuard | Cancer - Colorectal DNA test | Pivotal | Expects to complete its ongoing DeeP-C clinical trial for Cologuard during 2012 as well as making its FDA submission in 2012 | 02/24/2012 |
| EXEL | 4.61 | XL184 cabozantinib | Cancer - Ovarian | Phase 2 | Interim data released ASCO 2011 | 06/06/2011 |
| EXEL | 4.61 | XL184 cabozantinib | Cancer - Castration-Resistant Prostate Cancer | Phase 3 | Initiated Phase 3 Dec 2011, not under SPA | 02/09/2012 |
| EXEL | 4.61 | XL184 cabozantinib | Cancer - Castration-Resistant Prostate Cancer | Phase 3 | Initiate Phase 3 2Q 2012 - COMET-1 trial not under SPA | 05/04/2012 |
| EXEL | 4.61 | XL184 cabozantinib | Cancer - Medullary thyroid | NDA | Rolling NDA filing to be completed 1H 2012 | 02/10/2012 |
| EXEL | 4.61 | XL184 cabozantinib | Cancer - glioblastoma | Phase 2 | Ongoing | 08/13/2011 |
| EXEL | 4.61 | XL184 cabozantinib | Cancer - NSCLC | Phase 1/2 | Ongoing | 08/13/2011 |
| EXEL | 4.61 | XL184 cabozantinib | Cancer - Breast cancer | Phase 2 | Phase 2 initiated Nov 2011 | 11/21/2011 |
| EXEL | 4.61 | XL184 cabozantinib | Cancer - Breast cancer randomized discontinuation trial (RDT) | Phase 2 | Prelim data released Dec 2011 | 12/07/2011 |
| EXEL | 4.61 | XL 281 | Development halted | 07/15/2011 | ||
| FLML | 4.63 | IFN-Alpha-2b X | Hepatitis C HCV | Phase 2 | Ongoing | 04/07/2012 |
| FOLD | 4.67 | migalastat HCl monotherapy | Fabry Disease | Phase 3 | Completed enrolment Study 011 Dec '11. Data due 3Q 2012 | 05/12/2012 |
| FOLD | 4.67 | Migalastat HCl monotherapy | Fabry Disease | Phase 3 | Initiated Phase 3 Study 012 Fabry disease Sept 2011. Enrolment due to be completed by end of 2012. | 05/12/2012 |
| FOLD | 4.67 | Migalastat co-administered with enzyme replacement therapy (ERT) | Fabry Disease | Phase 2 | Interim Phase 2 Study 013 due 3Q12 with final results due at Fall 2012 scientific conference | 05/12/2012 |
| FOLD | 4.67 | AT2220/ERT enzyme replacement therapy | Pompe Disease | Phase 2 | Initiated Dec 2011, preliminary data from Phase 2 Study 010 due 2Q 2012 | 05/12/2012 |
| FURX | 15.76 | PPD-10558 | Dyslipidemia | Phase 2 | Data released Dec 2011. Missed endpoint. Cease further development | 12/09/2011 |
| FURX | 15.76 | MuDelta | Irritable bowel syndrome | Phase 2 | Initiate Phase 3 3Q 2012 | 03/08/2012 |
| FURX | 15.76 | JNJ-Q2 | Acute bacterial skin and skin structure infections (ABSSSI) | Phase 2 | Phase 3 planned pending funding | 04/07/2012 |
| FURX | 15.76 | JNJ-Q2 | Community acquired bacterial pneumonia (CABP) | Phase 2 | Enrolment terminated 2011 | 03/08/2012 |
| FURX | 15.76 | Alogliptin | Diabetes - Type 2 | CRL | Takeda resubmitted NDA July 26 2011, PDUFA 4/25/2012, issued CRL | 04/26/2012 |
| GALE | 1.49 | NeuVax (E75) | Cancer - low-to-intermediate HER2+ breast cancer | Phase 3 | Initiated Phase 3 Jan 2012 under SPA | 01/20/2012 |
| GENT | 9.63 | Defibrotide | VOD - treatment | NDA | NDA withdrawn 2011. Hopeful of submitting new NDA during 2012 | 03/28/2012 |
| GENT | 9.63 | Defibrotide | VOD - prevention | NDA | NDA withdrawn 2011. Hopeful of submitting new NDA during 2012 | 03/28/2012 |
| GERN | 1.37 | Imetelstat | Cancer - Breast | Phase 2 | Topline data due by end of 4Q 2012 | 05/04/2012 |
| GERN | 1.37 | Imetelstat | Cancer - Myeloma | Phase 2 | Topline data due by end of 4Q 2012 | 03/08/2012 |
| GERN | 1.37 | GRNOPC1 | Acute spinal cord injury | Phase 1 | Discontinued | 11/15/2011 |
| GERN | 1.37 | GRN1005 | Cancer - Brain Metastases - breast cancer | Phase 2 | Topline data due by end of 2Q 2013 | 03/08/2012 |
| GERN | 1.37 | GRN1005 | Cancer - Brain Metastases - NSCLC | Phase 2 | Topline data due by end of 2Q 2013 | 03/08/2012 |
| GERN | 1.37 | Imetelstat | Cancer - NSCLC | Phase 2 | Topline data due by end of 4Q 2012 | 05/04/2012 |
| GERN | 1.37 | Imetelstat | Cancer - essential thrombocythemia | Phase 2 | Topline data due by end of 4Q 2012 | 03/08/2012 |
| GEVA | 38.80 | SBC-102 | LAL Deficiency | Phase 1/2 | Interim data released Feb 2012 | 02/10/2012 |
| GNVC | 2.51 | Vaccine | FMD | |||
| GNVC | 2.51 | Vaccine | Malaria | |||
| GTXI | 2.97 | Ostarine | Cancer - muscle wasting in patients with non-small cell lung cancer | Phase 3 | Data 1Q 2013 | 02/22/2012 |
| GTXI | 2.97 | GTx-758 Capesaris | Cancer - Prostate | Phase 2b | Placed on clinical hold. Hold lifted May 2012. Intends to initiate Phase 2 trial on lower dose 3Q 2012 | 05/09/2012 |
| GTXI | 2.97 | Toremifene 80mg | Cancer - Prostate | CRL | Development terminated following CRL | 03/02/2011 |
| HALO | 7.90 | HTI-501 | Celluoite | Phase 1/2 | Phase 2 part of trial pending | 03/13/2012 |
| HALO | 7.90 | Herceptin | Cancer - Breast - Herceptin SC | MAA | Line Extension Application to the European Medicines Agency Mar 2012 | 04/07/2012 |
| HALO | 7.90 | Ultrafast Insulin | Diabetes | Phase 2 | Further data due 2012 | 04/07/2012 |
| HALO | 7.90 | HyQ | BLA | Informed by FDA that more data is required | 04/17/2012 | |
| HALO | 7.90 | PEGPH20 | Cancer - pancreatic | Phase 2 | Phase 1/2 Initiated Oct 2011 | 10/05/2011 |
| HALO | 7.90 | SC Cinryze | Hereditary angioedema (HAE) | Phase 2 | Prelim data released Dec 2011. Dose finding study to be initiated | 12/06/2011 |
| HALO | 7.90 | GAMMAGARD LIQUID - Baxter | Primary immunodeficiency disorders | Phase 3 | Filed for regulatory approval 2Q 2011 | 04/07/2012 |
| HALO | 7.90 | Subcutaneous (SC) MabThera (rituximab) - by Roche | Non-Hodgkin's lymphoma (NHL) - intravenous already approved | Phase 3 | Phase 3 ongoing. MAA submission due 2012 | 04/07/2012 |
| HEB | 0.25 | Ampligen - pig | CFS | CRL | Granted extension to resubmit NDA Jan 2012 | 04/07/2012 |
| HGSI | 13.99 | BENLYSTA | Vasculitis | Phase 3 | Initiate Phase 3 during 2012 | 01/13/2012 |
| HGSI | 13.99 | BENLYSTA | Active lupus nephritis | Phase 3 | Initiate Phase 3 during 2012 | 01/13/2012 |
| HGSI | 13.99 | Albiglutide | Type 2 diabetes | Phase 3 | Initial Phase 3 data due mid 2012 | 01/13/2012 |
| HGSI | 13.99 | Subcutaneous BENLYSTA | Lupus | Phase 3 | Initiated Phase 3 Dec 2012, data due 2H 2014 | 01/13/2012 |
| HGSI | 13.99 | Darapladib | Cardiovascular disease | Phase 3 | Enrolment completed October 2011 | 01/13/2012 |
| HGSI | 13.99 | Mapatumumab with sorafenib | Cancer - advanced hepatocellular | Phase 2 | Complete Phase 2 enrolment during 2012 | 01/13/2012 |
| HZNP | 3.80 | LODOTRA | Rheumetoid Arthritis | PDUFA | PDUFA 7/6/2012 | 11/30/2011 |
| IDIX | 8.08 | IDX899 | HIV | Phase 2b | Discontinued 2011 | 04/07/2012 |
| IDIX | 8.08 | IDX184 | Hepatitis C HCV | Phase 2b | Phase 2b interim data released Jan 2012, further data available 2H 2012 | 04/21/2012 |
| IDIX | 8.08 | IDX320 | Hepatitis C HCV | Phase 1/2 | Discontinues development due to SAE | 02/10/2011 |
| IDRA | 1.03 | IMO-2055 | Cancer - Squamous Cell, Head and Neck | Phase 2 | Phase 2 data released May 2012. Failed to meet endpoints | 05/04/2012 |
| IDRA | 1.03 | IMO-3100 | Psoriasis | Phase 2 | Phase 2 Initiated during April 2012, due to be completed 1H 2013 | 05/10/2012 |
| IDRA | 1.03 | IMO-2125 | Treatment-Naïve HCV | Phase 2 | Discontinued 2011 | 04/07/2012 |
| IMGN | 13.51 | IMGN901 lorvotuzumab mertansine | Cancer - small-cell lung cancer SCLC | Phase 2 | Initiate Phase 2 early 2Q 2012 | 04/07/2012 |
| IMGN | 13.51 | IMGN901 (lorvotuzumab mertansine) | Cancer - Merkel cell carcinoma | Pivotal pending | Initiate pivotal trial there is a benefit in aggressively developing IMGN901 for MCC as well as for SCLC | 08/29/2011 |
| IMGN | 13.51 | Trastuzumab emtansine ( T-DM1, trastuzumab-DM1) | Cancer - 1st-line HER2+ Metastatic Breast Cancer | Phase 2 | Phase 2 complete, positive data, file NDA 2014 | 08/29/2011 |
| IMGN | 13.51 | Trastuzumab emtansine ( T-DM1, trastuzumab-DM1) | Cancer - 3rd-line HER2+ MBC | BLA | Phase 3 initiated Sept 2011 | 10/28/2011 |
| IMGN | 13.51 | Trastuzumab emtansine ( T-DM1, trastuzumab-DM1) | Cancer - 2nd-line HER2+ MBC | Phase 3 | Phase 3 met PFS endpoint Mar 2012. NDA planned | 04/01/2012 |
| IMGN | 13.51 | SAR3419 | Cancer - NHL Non-Hodgkin lymphoma | Phase 2 | Initiated Phase 2 Oct 2011 | 10/20/2011 |
| IMMU | 3.40 | Epratuzumab | Lupus | Phase 3 | Data due 1H 2014 | 08/29/2011 |
| IMMU | 3.40 | Epratuzumab/ Rituximab | Cancer - non-Hodgkin's lymphoma / Follicular Lymphoma | Phase 2 | Initial data Dec 6 2010 | 12/07/2010 |
| IMMU | 3.40 | Veltuzumab | Rheumatoid Arthritis | Phase 2 | Ongoing | 04/07/2012 |
| IMMU | 3.40 | Clivatuzumab tetraxetan | Cancer - Pancreatic | Phase 3 | Phase 3 to commence once Phase 1b is completed | 05/12/2012 |
| IMMU | 3.40 | Veltuzumab intravenous | Cancer - NHL Non-Hodgkin lymphoma | Phase 2 | Phase 3 planned, need funding | 04/07/2012 |
| IMMU | 3.40 | Epratuzumab | Cancer - ALL | Phase 2 | Planning | 04/07/2012 |
| IMMU | 3.40 | Veltuzumab | Cancer - immune thrombocytopenic purpura - ITP | Phase 2 | Updated Phase 2 data presented at ASH Dec 2011 | 12/12/2011 |
| INCY | 21.75 | INCB18424 ruxolitinib | Myelofibrosis | PDUFA | Approved Nov 2011 | 11/20/2011 |
| INCY | 21.75 | LY3009104 | Rheumatoid arthritis | Phase 2 | Phase 2b data due later in 2012 | 04/26/2012 |
| INCY | 21.75 | LY3009104 | Psoriasis | Phase 2b | Phase 2b data due 2013 | 04/26/2012 |
| INCY | 21.75 | INCB18424 ruxolitinib | Polycythemia Vera | Phase 3 | Phase 3 data due 2H 2013 | 04/26/2012 |
| INCY | 21.75 | INCB18424 ruxolitinib | Cancer - Pancreatic | Phase 2 | Initiated July 2011. Data due 2H 2013 | 04/26/2012 |
| INCY | 21.75 | INCB7839 | Cancer - breast | Phase 2 | Discontinued 4Q 2011 | 10/28/2011 |
| INCY | 21.75 | INCB28060 | Cancer - Solid tumours | Phase 1/2 | Ongoing | 04/26/2012 |
| INCY | 21.75 | INCB24360 | Cancer - Melanoma | Phase 2 | Initiated Phase 2 by early 2Q 2012 | 04/26/2012 |
| INCY | 21.75 | INCB24360 | Cancer - Ovarian | Phase 1/2 | Initiate Phase 2 late 2012 | 04/26/2012 |
| INCY | 21.75 | INCB18424 | Cancer- Children with solid tumors, leukemia, or myeloproliferative neoplasms | Phase 1/2 | Ongoing | 02/16/2012 |
| INFI | 12.45 | IPI-145 | Inflammation | Phase 1 | Initiate Phase 2 2H 2012 | 03/14/2012 |
| INFI | 12.45 | Retaspimycin Hydrochloride with docetaxel | Cancer - NSCLC | Phase 2 | Aim to complete enrolment of Phase 2 2H 2012 | 03/14/2012 |
| INFI | 12.45 | Retaspimycin Hydrochloride with everolimus | Cancer - NSCLC | Phase 1b/2 | Aim to report topline data of dose-escalation portion of the Phase 1b/2 trial 2H 2012 | 01/04/2012 |
| INFI | 12.45 | IPI-926 Saridegib | Cancer - Pancreatic | Phase 2 | Phase 2 topline data due 2H 2012 | 01/04/2012 |
| INFI | 12.45 | IPI-926 Saridegib | Cancer - Chondrosarcoma | Phase 2 | Aim to complete enrolment of Phase 2 2H 2012 | 03/14/2012 |
| INFI | 12.45 | IPI-926 Saridegib | Myelofibrosis | Phase 2 | Phase 2 topline data due 2H 2012 | 03/14/2012 |
| INFI | 12.45 | Retaspimycin Hydrochloride | Cancer - Breast | Phase 2 | Discontinued | 08/04/2010 |
| INSM | 2.87 | ARIKACE | cystic fibrosis | Phase 3 | US Phase 3 on clinical hold lifted May 2012 | 05/08/2012 |
| INSM | 2.87 | ARIKACE | Nontuberculous Mycobacteria | Phase 2 | Clinical hold lifted Jan 2012. Phase 2 to be initiated mid 2012 | 03/14/2012 |
| INSM | 2.87 | IPLEX | MMD - Myotonic muscular dystrophy | Phase 2 | Announced early 2012 - no longer priority | 04/07/2012 |
| IPXL | 20.97 | IPX066 | Parkinson's | PDUFA | PDUFA date October 21 2012 | 02/24/2012 |
| IPXL | 20.97 | IPX159 | Restless Legs | Phase 2b | Phase 2b initiated Dec 2011. Data due mid 2013 | 12/21/2011 |
| IPXL | 20.97 | IPX056 | Multiple Sclerosis | Phase 3 | Second Phase 3 trial on hold | 12/21/2011 |
| IRWD | 11.27 | Linaclotide | chronic constipation | PDUFA | PDUFA date extended by 3 mths likely early Sept 2012 - | 04/23/2012 |
| IRWD | 11.27 | Linaclotide | irritable bowel syndrome with constipation (IBS‐C). | PDUFA | PDUFA date extended by 3 mths likely early Sept 2012 - | 04/23/2012 |
| ISIS | 8.95 | Mipomersen | Heterozygous FH | Phase 3 | Filed MAA Jul 27 2011 | 07/28/2011 |
| ISIS | 8.95 | ISIS-CRPRx | Atrial fibrillation | Phase 2 | Plan to initiate 2012 | 04/07/2012 |
| ISIS | 8.95 | ISIS-CRPRx | Rheumatoid arthritis | Phase 2 | Phase 2 ongoing | 04/07/2012 |
| ISIS | 8.95 | ISIS-CRPRx | Cancer - Multiple Myeloma | Phase 2 | Phase 2 pending | 09/02/2011 |
| ISIS | 8.95 | ISIS113715 | Diabetes | Phase 2 | Data reported | 08/09/2010 |
| ISIS | 8.95 | ISIS-EIF4ERx | Cancer - NSCLC | Phase 2 | Initiated Jan 2011 | 01/04/2011 |
| ISIS | 8.95 | ISIS-EIF4ERx | Cancer - Prostate | Phase 2 | Initiated Jan 2011 | 01/04/2011 |
| ISIS | 8.95 | ISIS-APOCIII | High triglycerides | Phase 2 | Initiated Phase 2 in May 2012 | 05/05/2012 |
| ISIS | 8.95 | ISIS-FXI | Clotting disorders | Phase 2 | Intend to initiate Phase 2 in 2012 | 04/07/2012 |
| ISIS | 8.95 | OGX-011 | Cancer - prostate | Phase 3 | Initiated 2Q 2010 | 08/09/2010 |
| ISIS | 8.95 | OGX-011 | Cancer - NSCLC | Phase 3 | Phase 3 pending | 04/07/2012 |
| ISIS | 8.95 | EXC 001 | Treatment following abdominal surgery | Phase 2 | Data reported 2Q 2010 | 08/09/2010 |
| ISIS | 8.95 | ACHN-490 | Phase 2 | Initiated 2Q 2010 | 08/09/2010 | |
| ISIS | 8.95 | Mipomersen (KYNAMRO) | Homozygous familial hypercholesterolemia (HoFH) | NDA | NDA filed Mar 29,2012, MAA filed July 27 2011 | 04/01/2012 |
| ISIS | 8.95 | LY2181308 | Cancer - Acute myeloid leukemia AML | Phase 2 | Aim to complete during 2012 | 04/07/2012 |
| ISTA | 9.07 | To be bought out by Bausch + Lomb 2Q 2012 | 03/27/2012 | |||
| ITMN | 10.08 | Pirfenidone | Idiopathic pulmonary fibrosis | Phase 3 | Data due 1H 2014 | 04/27/2012 |
| ITMN | 10.08 | Danoprevir | Hepatitis C HCV | Phase 2b | Sold to Roche Oct '10 | 10/07/2010 |
| JAZZ | 42.43 | Sodium oxybate | Fibromyalgia | CRL | CRL Oct 11 '10 | 10/11/2010 |
| JAZZ | 42.43 | Ropinirole gel | Restless Legs | Phase 2 | Development stopped | 08/10/2010 |
| JAZZ | 42.43 | Intranasal clonazepam | Epilepsy | Phase 2 | Evaluating development | 09/02/2011 |
| KERX | 1.54 | Zerenex | Hyperphosphatemia | Phase 3 | Short term efficacy final data presented April 28, 2011. NDA filing mid 1H 2012 | 04/28/2011 |
| KERX | 1.54 | Zerenex | Hyperphosphatemia | Phase 3 | Long term efficacy trial - aim to complete 4Q 2012 | 03/01/2012 |
| KERX | 1.54 | Perifosine | Cancer - Colorectal | Phase 3 | Primary endpoint not met Apr 2012 | 04/03/2012 |
| KERX | 1.54 | Perifosine | Cancer - Myeloma | Phase 3 | Returned license to AEZS. AEZS plans to continue development | 05/08/2012 |
| LGND | 11.71 | Bazedoxifene | Osteoporosis | NDA | ????????? | 08/06/2010 |
| LGND | 11.71 | Aprela | Menopausal symptoms | Phase 3 | NDA filing due soon as of May 2 2012 | 05/04/2012 |
| LGND | 11.71 | Promacta/Revolade | Hepatitis C HCV | Phase 3 | First of two Phase 3 trials yields positive data. Data to be presented at upcoming conference 4Q 2011. 2nd trial to be completed 3Q 2011. sNDA due to be filed 2012 | 04/07/2012 |
| LGND | 11.71 | Captisol-Enabled Melphalan | Cancer - multiple myeloma | Phase 2 | Phase 2 data released Nov 2011, initiate pivotal trial 2012 with NDA filing in 2013 | 02/24/2012 |
| LGND | 11.71 | BMS-582949 | Atherosclerosis | Phase 2 | Ongoing | 02/15/2011 |
| LGND | 11.71 | CC-930 | Idiopathic pulmonary fibrosis | Phase 2 | Initiated Jan 2011 | 02/15/2011 |
| LGND | 11.71 | MEDI-528 | Asthma | Phase 2 | Complete 3Q 2011 | 02/15/2011 |
| LGND | 11.71 | Dinaciclib | Cancer | Phase 3 | Phase 3 to be initiated by Merck | 05/04/2012 |
| LGND | 11.71 | Carfilzomib | Cancer - multiple myeloma | PDUFA | PDUFA July 27 2012. ODAC meeting Jun 20 2012 | 05/04/2012 |
| LGND | 11.71 | SCH 527123 | COPD and Asthma | Phase 2b | Complete 3Q 2012 | 02/15/2011 |
| LXRX | 1.51 | LX2931 | RA + autoimmune diseases | Phase 2 | Additional Ph2 trial initiated 3Q 2011. Data due 2Q 2012 | 04/07/2012 |
| LXRX | 1.51 | LX1032 | Ulcerative colitis | Phase 2 | Ongoing | 04/07/2012 |
| LXRX | 1.51 | LX1032 | Carcinoid Syndrome | Phase 2a | Data released Aug 2011 | 08/20/2011 |
| LXRX | 1.51 | LX4211 | Diabetes | Phase 2b | Phase 2b data due mid 2012 | 04/13/2012 |
| MAPP | 11.54 | LEVADEX | Migraine | CRL | CRL Mar 26 2012, meeting with FDA scheduled 2Q 2012 | 05/05/2012 |
| MAPP | 11.54 | MAP0005 | Asthma & chronic obstructive pulmonary disease (COPD) | Phase 2a | Data released 2008 | 12/21/2010 |
| MDCO | 20.88 | Oritavancin | ABSSSI | Phase 3 | Complete enrolment 2Q 2012. File NDA 1H 2013 | 03/01/2012 |
| MDCO | 20.88 | Cangrelor | Antiplatelet agent | Phase 3 | Ongoing | 03/01/2012 |
| MDCO | 20.88 | MDCO-2010 | Reduction of blood loss during surgery | Phase 2b | Plan to initiate Phase 2b trial 2Q 2012 | 03/01/2012 |
| MDGN | 5.78 | Erythropoietin ("EPO") therapy delivered via EPODURE Biopump | Anemia in dialysis patients with end-stage renal disease ("ESRD"). | Phase 2b | Phase 2b IND filed Apr 2012 for US trial. Phase 2a Israel trial to be initiated 2Q 2012 | 05/15/2012 |
| MDGN | 5.78 | INFRADURE | Hepatitis C HCV | Phase 2a | Two Phase I/II trials in Israel slated to commence in Q3 2012 | 05/15/2012 |
| MDVN | 83.15 | Dimebon | Alzheimer's disease | Phase 3 | Phase 3 fail. Development discontinued. | 01/17/2012 |
| MDVN | 83.15 | MDV3100 | Cancer - prostate 2nd line | Phase 3 | NDA to be filed 2Q 2012 seeking priority review | 05/09/2012 |
| MDVN | 83.15 | MDV3100 | Cancer - First line Prostate Cancer | Phase 2 | Initiated May 2011, enrolling | 04/07/2012 |
| MDVN | 83.15 | MDV3100 cf Bicalutamide | Cancer - prostate | Phase 2 | Initiated Mar 2011, enrolling | 04/07/2012 |
| MDVN | 83.15 | Dimebon | Huntington disease | Phase 3 | Topline HORIZON trial data released Apr 11 2011. FAILED. Ph3 CONCERT trial data due 1H 2012 | 05/08/2011 |
| MELA | 2.84 | Melafind | Cancer - melanoma detection | Approved | Approved Nov 2011 | 11/05/2011 |
| MNKD | 1.60 | MKC1106-MT | Cancer - advanced melanoma | Phase 2 | Initiated Oct 2010 | 10/20/2010 |
| MNKD | 1.60 | AFREZZA | Insulin | CRL | CRL received Jan 19, 2011. Data from two new trials due around end of 2012, NDA filing 1H 2013 | 03/16/2012 |
| MNOV | 3.07 | MN-166 | Multiple sclerosis | Phase 2 | Pending additional Ph2b, need partner | 08/19/2011 |
| MNOV | 3.07 | MN-166 | Chronic pain | Phase 2b | Funding required | 08/19/2011 |
| MNOV | 3.07 | MN-221 | Acute Asthma and COPD | Phase 2 | Prelim data due 2Q 2012 | 05/11/2012 |
| MNTA | 13.83 | Generic Copaxone | Multiple sclerosis | aNDA | Filed 2007. 30mth period where TEVA has protection from generics ends Jan 11 2011 | 12/12/2010 |
| MNTA | 13.83 | Generic Lovenox | Deep vein thrombosis | Approved | Approved July 2010 | 08/01/2010 |
| MNTA | 13.83 | M-118 | Acute coronary syndromes | Phase 2 | Need partner to further | |
| MNTA | 13.83 | M402 | Cancer - advanced metastatic pancreatic cancer | Phase 1/2 | Patient screening underway for Phase 1/2 proof of concept trial | 05/04/2012 |
| MYRX | 2.57 | Azixa | Cancer - Glioblastoma - 1st line | Phase 2b | Suspended future development of Azixa due to unlikely success | 09/09/2011 |
| MYRX | 2.57 | Azixa | Cancer - Glioblastoma - 2nd/3rd line | Phase 2a | Suspended future development of Azixa due to unlikely success | 09/09/2011 |
| MYRX | 2.57 | Azixa | Cancer - Relapsed Glioblastoma Multiforme | Phase 2 | Suspended future development of Azixa due to unlikely success | 09/09/2011 |
| MYRX | 2.57 | Azixa | Cancer - Melanoma | Phase 2a | Suspended future development of Azixa due to unlikely success | 09/09/2011 |
| NABI | 1.60 | NicVAX | Nicotine Addiction | Phase 3 | FAILED second Phase 3 trial | 11/07/2011 |
| NABI | 1.60 | NicVAX | Nicotine Addiction | Phase 3 | FAILED first of two Phase 3 trials July 2011 | 07/18/2011 |
| NAVB | 2.79 | RIGScan | Detection of solid tumours | Pre IND | Initiate trials 2012 | 11/20/2011 |
| NAVB | 2.79 | Lymphoseek | Lymphatic-tissue tracing agent | PDUFA | PDUFA Sep 10 2012. Three month extension due to data submitted to FDA within 90 days of original PDUFA date | 04/04/2012 |
| NBIX | 6.55 | Urocortin 2 | Cardiovascular diseases | Phase 2 | Phase 2 data released May 2012. Partner required for further development | 05/18/2012 |
| NBIX | 6.55 | Elagolix | Endometriosis | Phase 3 | Initiate Phase 3 2Q 2012 | 05/04/2012 |
| NBIX | 6.55 | Elagolix | Uterine Fibroids | Phase 2 | Abbott Initiated Phase 2 Sept 13 2011, to be completed late 2012 | 02/10/2012 |
| NBIX | 6.55 | VMAT2 NBI-98854 | Tardive dyskinesia | Phase 2 | Phase 2b to be initiated mid 2012 with data due end of 2012 | 05/04/2012 |
| NBIX | 6.55 | GSK561679 | Anxiety and Depression | Phase 2 | Endpoint not met Sept '10 | 09/15/2010 |
| NBY | 1.03 | NVC422 | Urine infection | Phase 2 | Phase 2 Topline Data due later in 2012 | 05/18/2012 |
| NBY | 1.03 | NVC422 | Viral conjunctivitis | Phase 2 | Initiated Phase 2b May 2012. Data 1H 2013 | 05/18/2012 |
| NBY | 1.03 | NVC422 | Impetigo skin infection study | Phase 2b | Start Ph2b later in 2012 | 05/18/2012 |
| NGSX | 0.33 | Qutenza | Neuropathic pain associated with HIV-associated peripheral neuropathy (HIV-PN) | PDUFA | PDUFA Mar 7 2012, Advisory Committee NEGATIVE vote Feb 9 2012 | 02/10/2012 |
| NGSX | 0.33 | NGX-1998 | Neuropathic pain | Phase 2 | End of Phase 2 meeting planned for 3Q 2012 with possible Phase 3 initiation late 2012 | 05/04/2012 |
| NKTR | 6.41 | NKTR-102 | Cancer - breast | Phase 3 | Phase 3 initiated Dec 2011 | 12/12/2011 |
| NKTR | 6.41 | NKTR-102 | Cancer - ovarian | Phase 2 | Ongoing | 04/07/2012 |
| NKTR | 6.41 | NKTR-102 | Cancer - colorectal | Phase 2 | Ongoing | 04/07/2012 |
| NKTR | 6.41 | NKTR-118 | Opioid bowel dysfunction | Phase 3 | Initiated Mar 2011, plan NDA filing 2013 | 11/05/2011 |
| NKTR | 6.41 | NKTR-181 | Chronic pain | Phase 2 | Initiate Phase 2 mid 2012 | 04/07/2012 |
| NKTR | 6.41 | Amikacin Inhale | Phase 2 | Phase 3 pending | 04/07/2012 | |
| NLNK | 11.21 | HyperAcute Pancreas | Cancer - pancreatic | Phase 3 | Interim Phase 3 data due late 2012, complete enrolment 2013. Second interim read late 2013 | 04/07/2012 |
| NLNK | 11.21 | HyperAcute Lung | Cancer - NSCLC | Phase 2b/3 | Initiate Phase 2b/3 1H 2012 | 04/07/2012 |
| NLNK | 11.21 | HyperAcute Melanoma | Cancer - melanoma | Phase 2 | Phase 2 data due 1H 2012 | 04/07/2012 |
| NPSP | 7.13 | GATTEX | Short Bowel Syndrome | PDUFA | PDUFA date September 30 2012 | 02/16/2012 |
| NPSP | 7.13 | NPSP558 | Hypoparathyroidism | Phase 3 | Positive Phase 3 data released Nov 2011. File BLA end of 2012 | 02/16/2012 |
| NVAX | 1.16 | VLP | Seasonal Flu | Phase 2 | Data released Feb 2011 | 02/18/2011 |
| NVAX | 1.16 | Seasonal Influenza Vaccine | Seasonal Flu | Phase 2 | Phase 2 initiated Mar 2012. Topline data due 3Q 2012 | 03/02/2012 |
| NVGN | 2.33 | GLYC-101 Gel | Wound healing | Phase 2 | Phase 2 completed | 09/02/2011 |
| NVGN | 2.33 | Phenoxodiol | Cancer - Ovarian | Phase 3 | Endpoints not met June 1 '10 | 06/06/2010 |
| NVGN | 2.33 | Phenoxodiol intravenous | Cancer - Ovarian | Phase 2 | Phase 2 completed | 09/02/2011 |
| NYMX | 7.69 | NX-1207 | BPH | Phase 3 | Ongoing | 04/07/2012 |
| NYMX | 7.69 | NX-1207 | Cancer - low grade localized prostate | Phase 2 | Phase 2 initiated Mar 2012 | 03/02/2012 |
| OGXI | 12.73 | Custirsen | Cancer - castrate-resistant prostate | Phase 3 | Complete enrolment 2H 2012 | 03/11/2012 |
| OGXI | 12.73 | Custirsen | Cancer - castrate-resistant prostate - trial 2 | Phase 3 | Initiate 2nd Phase 3 trial 2H 2012 | 03/11/2012 |
| OGXI | 12.73 | Custirsen | Cancer - NSCLC | Phase 3 | Initiate 2H 2012 | 05/04/2012 |
| OGXI | 12.73 | OGX-427 | Cancer - prostate | Phase 2 | Prelim Phase 2 data released Feb 2012 | 02/03/2012 |
| OGXI | 12.73 | OGX-427 | Cancer - bladder | Phase 2 | Phase 2 enrolling | 05/04/2012 |
| OGXI | 12.73 | OGX-427 | Cancer - castrate-resistant prostate | Phase 2 | Initiate Phase 2 later in 2012 | 05/04/2012 |
| OMER | 9.52 | OMS103HP | ACL | Phase 3 | Disappointing Data released Mar 2011 | 04/01/2011 |
| OMER | 9.52 | OMS103HP | Postoperative joint function | Phase 3 | Data due 2H 2012 | 05/11/2012 |
| OMER | 9.52 | OMS302 | cataract surgery | Phase 3 | Met primary and secondary endpoints Mar 2012. Additional Phase 3 trial initiated early April 2012 with data 2H 2012. NDA filing due first part of 2013 | 04/11/2012 |
| OMER | 9.52 | OMS201 | Urology | Phase 1/2 | Interim Data released Dec 2010 | 12/29/2010 |
| ONCY | 3.48 | REOLYSIN with paclitaxel | Cancer - ovarian, fallopian tube or primary peritoneal | Phase 2 | Ongoing | 04/08/2012 |
| ONCY | 3.48 | REOLYSIN | Cancer - Head and Neck | Phase 3 | First stage of Phase 3 enrolment completed | 04/03/2012 |
| ONCY | 3.48 | Intravenous REOLYSIN with paclitaxel & carboplatin | Cancer - Head and Neck | Phase 2 | Data released Nov 2011 | 12/13/2011 |
| ONCY | 3.48 | REOLYSIN - intravenous with gemcitabine | Cancer - Pancreatic | Phase 2 | Interim data released Dec 2012 | 12/02/2011 |
| ONCY | 3.48 | REOLYSIN | Cancer - NSCLC | Phase 2 | Ongoing | 04/08/2012 |
| ONCY | 3.48 | REOLYSIN | Cancer - advanced or metastatic colorectal cancer | Phase 2 | Phase 2 planned | 05/04/2012 |
| ONTY | 3.43 | Stimuvax | Cancer - NSCLC | Phase 3 | Data due 2013 | 03/07/2012 |
| ONTY | 3.43 | PX-866 | Cancer - metastatic colorectal carcinoma (CRC) & squamous cell carcinoma of the head and neck (SCCHN) | Phase 1/2 | Initiated Phase 2 Oct 2011 | 10/20/2011 |
| ONTY | 3.43 | PX-866 | Cancer - Glioblastoma | Phase 2 | Initiated Phase 2 April 2011. Ongoing | 04/08/2012 |
| ONTY | 3.43 | Stimuvax | Cancer - Breast | Phase 3 | Trial cancelled | 08/06/2010 |
| ONTY | 3.43 | PX-866 | Cancer - prostate | Phase 2 | Initiated Phase 2 Sept 2011 | 09/13/2011 |
| OPTR | 14.81 | Fidaxomicin | CDI - diarrhea | Approved | FDA Approved May 27 2011 | 05/27/2011 |
| OPTR | 14.81 | Pruvel | Infectious diarrhea | Phase 3 | NDA filing on hold due to rash in Ph3 trials | 05/21/2011 |
| OPTR | 14.81 | OPT-822/821 | Cancer - metastatic breast cancer | Phase 2/3 | Phase 2/3 initiated Dec 2010 | 03/09/2012 |
| OPXA | 0.47 | Tovaxin | Relapsing Remitting MS (RRMS) | Phase 3 | Phase 3 pending | 04/08/2012 |
| OPXA | 0.47 | Tovaxin | Secondary Progressive MS (SPMS) | Phase 2 | Phase 2b pending, possibly by end of 2012, need funding | 02/28/2012 |
| OREX | 3.44 | Empatic | Epilepsy | Phase 2b | Evaluate next steps for the Empatic once have had an opportunity to review regulatory outcome for Vivus Qnexa | 04/08/2012 |
| OREX | 3.44 | Contrave | Obesity | CRL | CRL Feb 1, 2011, expect to initiate cardiovascular outcomes trial late 2Q 2012 under SPA with possible NDA filing mid-2014 | 05/12/2012 |
| OSIR | 5.55 | Prochymal | Crohn’s disease | Phase 3 | Enrollment re-started May '10.Ongoing | 04/08/2012 |
| OSIR | 5.55 | Prochymal | Refractory GvHD | Terminated | Terminated Feb 2012 | 04/08/2012 |
| OSIR | 5.55 | Prochymal | Acute myocardial infarction | Phase 2 | Enrolment completed Mar 2011. Ongoing | 04/08/2012 |
| OSIR | 5.55 | Prochymal | Diabetes | Phase 2 | Failed trial Jan 2012 | 01/03/2012 |
| OSUR | 10.40 | OraQuick | HIV test | FDA Blood Products Advisory Committee (BPAC) to met May 15, 2012. Unanimous positive vote | 05/16/2012 | |
| OXGN | 0.88 | ZYBRESTAT | Cancer - ATC | Phase 2/3 | Hope to initiate Phase 3 in 4Q 2012 | 05/10/2012 |
| OXGN | 0.88 | ZYBRESTAT | Cancer - NSCLC | Phase 2 | Concluding development | 09/01/2011 |
| OXGN | 0.88 | ZYBRESTAT | Cancer - Ovarian | Phase 2 | Initiated Apr 2011, data due early 2013 | 04/08/2012 |
| PATH | 3.03 | Zelrix | Migraine | CRL | CRL Aug 31 2011, resubmit NDA 1H 2012 | 05/11/2012 |
| PBMD | 4.84 | CVac | Cancer - ovarian | Phase 3 | Phase 3 initiated Jan 2012. Full patient enrolment should be complete by around Q3-Q4 2013, with data expected in 2015. | 04/18/2012 |
| PBTH | 4.95 | hGH-CTP | Adults - growth hormone deficiency | Phase 2 | Initiate Phase 3 during 2012 | 04/09/2012 |
| PBTH | 4.95 | hGH-CTP | Children - growth hormone deficiency | Phase 2 | Initiated Phase 2 | 04/09/2012 |
| PCRX | 10.15 | EXPAREL | Postsurgical pain | Approved | FDA Approved October 2011 | 10/31/2011 |
| PCYC | 28.60 | PCI-24781 | Cancer - lymphoma | Phase 2 | Complete enrolment 1Q 2012 | 02/10/2012 |
| PCYC | 28.60 | PCI-32765 (PCYC-1111) | Cancer - relapsed/refractory multiple myeloma (MM) | Phase 2 | Initiate Phase 2 Q1 2012. Complete enrolment early 2013 | 02/10/2012 |
| PCYC | 28.60 | PCI-32765 in combination with ofatumumab (PCYC-1109) | Cancer - Chronic Lymphocytic Leukemia/Small Cell Lymphocytic Lymphoma (CLL/SLL) | Phase 2 | Complete Phase 2 enrolment 1H 2012. Some data to be released mid 2012 | 02/10/2012 |
| PCYC | 28.60 | PCI-32765 (PCYC-1102) | Cancer - Chronic Lymphocytic Leukemia/Small Cell Lymphocytic Lymphoma (CLL/SLL) | Phase 2 | Phase 2 enrolment complete.Interim data mid 2012. Expect to hear of Phase 3 design in 2Q 2012 | 02/10/2012 |
| PCYC | 28.60 | PCI-32765 (PCYC-1104) | Cancer - relapsed or refractory MCL | Phase 2 | Interim data presented at ASH 2011 - complete enrolment 1H 2012. Expect to hear of Phase 3 design in 2Q 2012 | 02/10/2012 |
| PCYC | 28.60 | PCI-32765 (PCYC-1106) | Cancer - Diffuse Large B-cell Lymphoma (DLBCL) | Phase 2 | Complete enrolment 1H 2012 | 02/10/2012 |
| PCYC | 28.60 | PCI-27483 | Cancer - pancreatic | Phase 2 | Interim data due 1H 2012 | 02/10/2012 |
| PGNX | 7.52 | RELISTOR pre-filled syringes | advanced-illness | Approved | Approved | 09/29/2010 |
| PGNX | 7.52 | Subcutaneous RELISTOR | chronic pain | sNDA | PDUFA Jul 27 2012 - extended by 3 months | 04/26/2012 |
| PGNX | 7.52 | Oral Methylnaltrexone | Chronic, Non-Cancer Pain Subjects with Opioid-Induced Constipation | Phase 3 | NDA filing due mid 2012 following Phase 3 data release Dec 2011 | 12/20/2011 |
| PLX | 6.20 | Taligluerase | Gaucher disease | Approved | Approved May 1 2012 | 05/02/2012 |
| POZN | 6.49 | PA32540 | Cardiovascular patients at risk for developing aspirin-associated gastric ulcers | Phase 3 | Phase3 endpoints met March 2012, intended to file NDA 3Q 2012 but delayed 6 months to 1Q 2014 following FDA meeting | 04/27/2012 |
| PPHM | 0.44 | Cotara | Cancer - Glioblastoma | Phase 2 | FDA to provide written feedback regarding Phase 3 design. Needs partner to advance | 03/11/2012 |
| PPHM | 0.44 | Bavituximab + ribavirin | Cancer - pancreatic | Phase 2 | Interim data due sometime 2012 | 03/11/2012 |
| PPHM | 0.44 | Bavituximab | HCV | Phase 2 | Phase 2 prelim data released Dec 2012. Seeking partner to advance program | 03/11/2012 |
| PPHM | 0.44 | Bavituximab | Cancer - Liver | Phase 1/2 | Initiated Dec 2010, ongoing | 09/09/2011 |
| PPHM | 0.44 | Bavituximab | Cancer - front-line NSCLC | Phase 2b | PFS disappointing data released Mar 2011. OS data due 2H 2012 | 03/11/2012 |
| PPHM | 0.44 | Bavituximab | Cancer - Refractory NSCLC | Phase 2 | Enrolment completed Oct 2011, data 1H 2012 | 03/11/2012 |
| PRAN | 1.62 | PBT-2 | Alzheimer's | Phase 2 | Phase initiated March 2012 | 03/08/2012 |
| PRAN | 1.62 | PBT-2 | Huntington's Disease | Phase 2 | Initiated Apr 2012 | 05/01/2012 |
| PSDV | 2.00 | Iluvien | Diabetic macular edema | CRL | CRL Nov 2011, two new trials required | 11/11/2011 |
| PSTI | 2.53 | PLX-PAD (stem cells) | CLI - Critical limb ischemia | Phase 1 | Phase 2/3 planned | 09/16/2011 |
| PSTI | 2.53 | PLX cells | Buerger's Disease | Phase 2 | Phase 2 planned in India | 09/16/2011 |
| PTIE | 3.78 | Remoxy | Chronic pain | CRL | CRL Jun 23, 2011 | 06/27/2011 |
| PTN | 0.60 | Subcutaneous Bremelanotide | Erectile Dysfunction | Phase 2 | Seeking partner for Phase 2 | 09/18/2011 |
| PTN | 0.60 | PL-3994 | Acute exacerbations of asthma | Phase 2 | Pending, FDA gives thumbs up for Phase 2 initiation | 03/03/2011 |
| PTN | 0.60 | Bremelanotide | female sexual dysfunction (FSD) | Phase 2b | Phase 2b initiated Jun 2011, enrolment completed Mar 2012, data expected 3Q 2012. Phase 3 initiation possible 1H 2013 dependent on funding | 03/09/2012 |
| QLTI | 6.70 | punctal plug drug delivery | Glaucoma | Phase 2 | Data released Aug 28 2011, further Phase 2 trial data to be released 2H 2012 with Phase 3 commencing 2013 pending positive Phase 2 data | 02/24/2012 |
| QLTI | 6.70 | punctal plug drug delivery | Allergic conjunctivitis | Phase 2a | Data released Feb 2011, trial failed, study stopped | 02/09/2011 |
| RGEN | 4.48 | RG1068 - SecreFlo | Pancreatic imaging | Phase 3 | PDUFA June 21 2012 under priority review. Gastrointestinal Drugs Advisory Committee meeting scheduled for May 31,2012 has been cancelled. CRL expected. | 04/26/2012 |
| RGEN | 4.48 | RG2417 | Bipolar | Phase 2b | Data released Mar 2011. FAIL | 02/09/2011 |
| RIGL | 7.55 | Fostamatinib | RA - rheumatoid arthritis | Phase 3 | Interim data due 2H 2012, NDA filing 2H 2013 | 03/07/2012 |
| RIGL | 7.55 | R343 | Asthma | Phase 2 | Initiate Phase 2 during late summer 2012 | 05/17/2012 |
| RIGL | 7.55 | R333 | Discoid Lupus Erythematosus | Phase 2 | Initiate Phase 2 during summer 2012 | 05/02/2012 |
| RNN | 0.40 | Archexin | Cancer - pancreatic | Phase 2a | Phase 2 data due 3Q 2012 | 01/17/2012 |
| RNN | 0.40 | Serdaxin | Major Depressive Disorder | Phase 2b | Failed to display efficacy | 12/13/2011 |
| RNN | 0.40 | Zoraxel | Erectile Dysfunction | Phase 2b | Phase 2b pending | 04/08/2012 |
| RPRX | 7.40 | Proellex | Endometriosis | Phase 2 | Type B meeting to be scheduled with the FDA during 2Q 2012, followed by initiation of Phase 2/3 trial during 3Q 2012 | 03/28/2012 |
| RPRX | 7.40 | Proellex | Uterine fibroids | Phase 2 | Phase 2 data for uterine fibroids due 4Q 2012, followed by End of Phase 2 meeting with FDA and possible Phase 3 initiation late 2012 or early 2013 | 05/01/2012 |
| RPRX | 7.40 | Androxal | Type 2 Diabetes | Phase 2 | Topline data released Dec 2011, plans to meet with FDA | 12/13/2011 |
| RPRX | 7.40 | Androxal | Secondary hypogonadism | Phase 2 | Meet with FDA 1H May 2012 re design of Phase 3 trial with possible NDA filing ealry 2014 | 03/28/2012 |
| RPTP | 5.33 | DR Cysteamine | Huntington's Disease | Phase 2 | Initiated Nov 2010 | 11/09/2010 |
| RPTP | 5.33 | DR Cysteamine | NASH | Phase 2b | Phase 2b initiate 1Q 2012 | 12/19/2011 |
| RPTP | 5.33 | DR Cysteamine | Cystinosis | Phase 3 | Filed NDA Mar 30, 2012 seeking 6 month priority review | 04/01/2012 |
| RPTP | 5.33 | Convivia | ALDH2 | Phase 2a | Phase 2 completed, seeking partner | 09/17/2011 |
| RPTP | 5.33 | Tezampanel | Thrombotic Disorder | Phase 1 | Initiate by end of year | 09/18/2011 |
| RVX | 1.36 | RVX-208 (SUSTAIN trial) | Coronary placque removal | Phase 2b | Enrolment completed Nov 2011. Data due 3Q 2012 | 05/10/2012 |
| RVX | 1.36 | RVX-208 (ASSURE trial) | Coronary placque removal | Phase 2b | Initiated Nov 2011. Data due Q1 2013 | 05/10/2012 |
| SCLN | 5.80 | SCV-07 | OM - oral mucositis | Discontinued | Discontinued Mar 2012 | 03/03/2012 |
| SCLN | 5.80 | SCV-07 | Hepatitis C HCV | Phase 2b stopped | Data released Dec 2010, discontinues development | 12/15/2010 |
| SCLN | 5.80 | ZADAXIN | H1N1 | Clinical | Final data released June 2010 | 06/30/2010 |
| SCMP | 8.00 | Amitiza/ Lubiprostone | Chronic idiopathic constipation | Phase 3 | Efficacy data released May 2011, MAA filed Aug 2011, expect MAA decision Aug 2012 | 03/14/2012 |
| SCMP | 8.00 | Amitiza/ Lubiprostone | Opioid-induced bowel dysfunction | Phase 3 | Met endpoint, sNDA filing due mid-2012 | 05/10/2012 |
| SCMP | 8.00 | Cobiprostone | Gastric ulcers | Phase 2a | Completed, data reported | 08/13/2011 |
| SCMP | 8.00 | Unoprostone isopropyl - rescula | Dry age-related macular degeneration (dry AMD) | Phase 2 | Initiate late 2012 | 03/14/2012 |
| SGEN | 20.06 | Lintuzumab | Cancer - Acute myeloid leukemia AML | Phase 2b | FAIL - Data Sept 13 2010 | 09/13/2010 |
| SGEN | 20.06 | Brentuximab Vedotin -ADCETRIS | Cancer - Anaplastic large cell lymphoma | Approved | APPROVED Aug 19 2011 | 08/20/2011 |
| SGEN | 20.06 | Brentuximab Vedotin -ADCETRIS | Cancer - Relapsed & Refractory Hodgkin lymphoma | Approved | APPROVED Aug 19 2011 | 08/20/2011 |
| SGEN | 20.06 | Brentuximab Vedotin -ADCETRIS | Cancer - CD30-positive non-Hodgkin lymphoma | Phase 2 | Initiated Aug 2011 | 08/23/2011 |
| SGEN | 20.06 | Brentuximab Vedotin -ADCETRIS | Cancer - CD30-positive non-lymphoma | Phase 2 | Initiated Phase 2 Oct 2011 | 10/26/2011 |
| SGEN | 20.06 | Brentuximab Vedotin -ADCETRIS | Cancer - cutaneous T-cell lymphoma | Phase 3 | Initiated May 2012 | 05/08/2012 |
| SGEN | 20.06 | Brentuximab Vedotin -ADCETRIS | Cancer - front-line advanced stage Hodgkin lymphoma | Phase 3 | Plan to initiate Phase 3 late 2012/early 2013 | 05/08/2012 |
| SGEN | 20.06 | Brentuximab Vedotin -ADCETRIS | Cancer - front-line mature T-cell lymphomas, including sALCL | Phase 3 | Plan to initiate Phase 3 late 2012/early 2013 | 05/08/2012 |
| SGMO | 4.35 | SB-728-902 | HIV/AIDS | Phase 2 | Phase 2 initiated Jan 2012 | 01/09/2012 |
| SGMO | 4.35 | SB-728-1101 | HIV/AIDS | Phase 2 | Phase 2 initiated Jan 2012 | 01/09/2012 |
| SGMO | 4.35 | SB-509-901 | Diabetic Neuropathy | Phase 2b | Data 4Q 2011 - FAILED | 10/04/2011 |
| SGYP | 4.32 | Plecanatide | Chronic idiopathic constipation (CIC) | Phase 2 / 3 | Initiated Phase 2/3 trial Nov 2011. Topline data due 4Q 2012 | 04/10/2012 |
| SGYP | 4.32 | Plecanatide | IBS-C | Phase 2 | Initiate sometime during 2012 | 04/08/2012 |
| SNSS | 2.63 | Voreloxin | Cancer - Acute myeloid leukemia AML | Phase 3 | Initiated Dec 2010, interim analysis 3Q 2012 | 05/16/2012 |
| SNSS | 2.63 | Voreloxin | Cancer - Ovarian | Phase 2 | Completed 2010 | |
| SNTA | 3.80 | Elesclomol | Cancer - ovarian | Phase 2 | Ongoing | 04/08/2012 |
| SNTA | 3.80 | STA-9090 Ganetespib | Cancer - NSCLC | Phase 2b /3 | Interim Phase 2b results due 2Q. Final PFS data and preliminary OS data from Phase 2b portion is expected in 2H 2012 and initiation of the Phase 3 portion expected during 2H 2012. | 05/04/2012 |
| SNTA | 3.80 | STA-9090 Ganetespib | Cancer - breast | Phase 2 | Phase 2 pending | 04/08/2012 |
| SNTA | 3.80 | STA-9090 Ganetespib | Cancer - gastrointestinal stromal tumors | Phase 2 | Data presented at ASCO 2011 | 09/17/2011 |
| SNTA | 3.80 | STA-9090 Ganetespib | Cancer - hepatic | Phase 1/2 | Ongoing | 04/08/2012 |
| SNTA | 3.80 | STA-9090 Ganetespib | Cancer - small cell lung | Phase 2 | Ongoing | 04/08/2012 |
| SNTA | 3.80 | STA-9090 Ganetespib | Cancer - AML | Phase 2b | Pending | 04/08/2012 |
| SNTA | 3.80 | STA-9090 Ganetespib | Cancer - rectal | Phase 1b/2 | Initiate Phase 1b/2 trial 1Q 2012 | 11/11/2011 |
| SNTA | 3.80 | Elesclomol | Cancer - AML | Phase 2 | Ongoing | 09/17/2011 |
| SNTA | 3.80 | Elesclomol | Cancer - NSCLC | Phase 2 | Initiate Ph2b sometime during 2012 | 01/05/2012 |
| SNTS | 5.64 | Budesonide - US | Ulcerative colitis disease | Phase 3 | Filed NDA Dec20 2011, NDA accepted. PDUFA Oct 16 2012 | 03/06/2012 |
| SNTS | 5.64 | Rifamycin | Travelers’ diarrhea | Phase 3 | Initiated June 2010, ongoing. Aim to complete 2H 2012 | 04/08/2012 |
| SNTS | 5.64 | RHUCIN | Hereditary Angioedema (HAE) attacks | Phase 3 | Expects to be completed 3Q 2012 | 02/14/2012 |
| SOMX | 0.32 | Silenor | Insomnia | Approved | 1Q 2010 | |
| SPEX | 0.76 | D-Tagatose | Diabetes | Phase 3 | Development stopped | 04/08/2012 |
| SPPI | 11.08 | Belinostat | Cancer - Carcinoma of Unknown Primary (CUP) | Phase 2 | Completed enrolment Dec 2010, data due 2H 2012 | 03/03/2012 |
| SPPI | 11.08 | ZEVALIN and Motexafin Gadolinium (MGd) | Non-Hodgkin's lymphoma (NHL) | Phase 2 | Phase 2 Initiated May 2012 | |
| SPPI | 11.08 | Fusilev | Cancer - Colorectal | Approved | Approved April 29 2011 | 05/01/2011 |
| SPPI | 11.08 | Fusilev | Cancer - Removal of Bioscan | Approved | Approved Nov 20, 2011 | 11/21/2011 |
| SPPI | 11.08 | Belinostat | Cancer - Peripheral T-Cell Lymphoma | Phase 3 | Enrolment completed Sept 2011. Data expected 4Q 2012 | 04/26/2012 |
| SPPI | 11.08 | Apaziquone | Cancer - Bladder | Phase 3 | Failed to meet primary endpoint in Phase 3 trial - Apr 2012. Some secondary endpoints met | 04/06/2012 |
| SQNM | 4.25 | SensiGene T21 Laboratory Developed Test (LDT) - MaterniT21 | Prenatal test for Down Syndrome | R&D | Launched Oct 2011 | 10/17/2011 |
| STEM | 0.80 | HuCNS-SC cells | NCL | Phase 1 | Discontinued due to lack of patient enrolment | 04/09/2011 |
| STEM | 0.80 | HuCNS-SC cells | Pelizaeus-Merzbacher disease (PMD) | Phase 1/2 | Prelim data from 4 patients released Apr 2012 | 04/03/2012 |
| STEM | 0.80 | HuCNS-SC cells | Spinal cord injury | Phase 1/2 | Interim data released May 2012 | 05/18/2012 |
| STEM | 0.80 | Age-Related Macular Degeneration | Phase 1 | Phase I/II to be initiated early 2012 | 07/29/2011 | |
| SUPN | 6.30 | SPN-538 | Epilepsy | PDUFA | PDUFA July 2012 | 04/27/2012 |
| SUPN | 6.30 | SPN-804 | Adjunctive therapy for epilepsy | PDUFA | PDUFA October 2012 | 04/27/2012 |
| SUPN | 6.30 | SPN-810 | Impulsive Aggression in ADHD | Phase 2b | Phase 2b data due 2H 2012 | 04/27/2012 |
| SUPN | 6.30 | SPN-810 | ADHD | Phase 2a | Completed 1Q 2011 | 04/27/2012 |
| SVNT | 0.85 | KRYSTEXXA | Chronic gout | Approved | FDA Approved. MAA submitted May 4 2011, expect approval 2Q 2012 est | 05/04/2011 |
| SYN | 2.25 | Trimesta | Multiple sclerosis | Phase 2 | Enrolment completed Mar 2012 | 03/15/2012 |
| SYN | 2.25 | Trimesta | Multiple sclerosis | Phase 2 | Phase 2 initiated Jan 2012 | 01/19/2012 |
| SYN | 2.25 | Flupirtine | Fibromyalgia | Phase 2 | Ongoing | 04/08/2012 |
| SYN | 2.25 | AEN-100 | ALS | Phase 2/3 | Planning | 04/08/2012 |
| TELK | 3.67 | TELINTRA | Myelodysplastic Syndrome | Phase 2 | Phase 2b initiated Oct 2011 | 10/13/2011 |
| TELK | 3.67 | TELINTRA | Lenalidomide | Phase 2 | Phase 2 Initiated June 2011, interim data due early 2013 | 09/03/2011 |
| THLD | 6.11 | TH-302 | Cancer - soft tissue sarcoma (406 trial) | Phase 3 | Initiated Ph3 Sept 2011, under SPA, interim data due early 2013 | 03/09/2012 |
| THLD | 6.11 | TH-302 | Cancer - Pancreatic | Phase 2b | Phase 2b data released Feb 2012. Primary endpoint PFS met. Overall survival data due 2H 2012 | 05/04/2012 |
| THLD | 6.11 | TH-302 | Cancer - multiple myeloma (408 trial) | Phase 1/2 | Phase 1/2 topline data due by end of 2012 | 05/04/2012 |
| THLD | 6.11 | TH-302 in Combination with Sunitinib | Cancer - renal cell carcinoma, gastrointestinal stromal tumors or pancreatic neuroendocrine tumors (410 trial) | Phase 1/2 | Phase 1/2 topline data due by end of 2012 | 05/04/2012 |
| THRX | 20.33 | Relovair | Asthma | Phase 3 | Phase 3 Data released Jan 2012. MAA to filed mid 2012. NDA finding pending following further discussions | 04/27/2012 |
| THRX | 20.33 | Relovair | Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Phase 3 Data released Jan 2012. MAA and NDA to filed mid 2012. | 04/27/2012 |
| THRX | 20.33 | GSK961081 | Chronic Obstructive Pulmonary Disease (COPD) | Phase 2b | Phase 2 completed | 04/27/2012 |
| THRX | 20.33 | TD−1211 | Opioid-induced constipation (OIC) | Phase 2b | Phase 2b data due mid 2012 | 04/27/2012 |
| THRX | 20.33 | TD-9855 | Attention deficit/hyperactivity disorder (ADHD) | Phase 2 | Phase 2 ongoing | 04/27/2012 |
| TLON | 0.75 | Marqibo | 2nd line adult Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) | PDUFA | PDUFA extended to Aug 12 2012. ODAC voted 7 yes, 4 no, and 2 abstain - Mar 21 2012 | 05/08/2012 |
| TRGT | 4.12 | TC-5214 | Major depressive disorder (MDD) | Phase 3 | Phase 3 (RENAISSANCE 2 and RENAISSANCE 3 missed primary endpoint | 02/22/2012 |
| TRGT | 4.12 | TC-5214 | Major depressive disorder (MDD) | Phase 3 | (RENAISSANCE 4 and RENAISSANCE 5) - failed to meet primary endpoint Mar 2012. Discontinue development | 03/21/2012 |
| TRGT | 4.12 | TC-5214 | Switch monotherapy | Phase 2b | Discontinued Mar 2012 | 03/27/2012 |
| TRGT | 4.12 | TC-5214 | Schizophrenia | Phase 2b | Phase 2b Ongoing | 02/22/2012 |
| TRGT | 4.12 | TC-5214 | Attention deficit/hyperactivity disorder (ADHD) | Phase 2 | Phase 2 topline data due 2H 2012 | 02/22/2012 |
| TRGT | 4.12 | TC-6987 | Type 2 Diabetes | Phase 2 | Phase 2 topline data released Mar 2012. Failed trial. Will not further development | 03/28/2012 |
| TRGT | 4.12 | TC-6987 | Asthma | Phase 2 | Phase 2 data released Mar 2012, originally met co-primary endpoints BUT revised data showed that it failed to meet one of the two endpoints | 04/11/2012 |
| TRGT | 4.12 | AZD3480 | Alzheimer’s disease | Phase 2b | Phase 2b Ongoing | 02/22/2012 |
| TRGT | 4.12 | AZD1446 | Alzheimer’s disease | Phase 2 | Phase 2 planned | 02/22/2012 |
| TSPT | 6.99 | Intermezzo | Insomnia | Approved | Approved Nov 2011 | 11/23/2011 |
| TSPT | 6.99 | Ondansetron TO-2061 | Obsessive Compulsive Disorder | Phase 2 | Data due 1Q 2013 | 04/03/2012 |
| TSRX | 4.99 | Oral torezolid phosphate | Acute bacterial skin and skin structure infections (ABSSSI) | Phase 3 | Topline data of first Phase 3 trial released Dec2011. SPA for second Ph3 initiated Sept 2011 data due early 2013 | 12/19/2011 |
| TTHI | 1.90 | TT-223 | Diabetes | Phase 2 | Endpoints NOT met Sept '10, development stopped | 11/12/2010 |
| TTHI | 1.90 | ELND005 | Alzheimer's | Phase 2 | Plan Ph3 despite average Ph2 | 12/02/2011 |
| TZYM | 3.00 | Ulimorelin ULISES 007 | To accelerate GI recovery in subjects who have undergone partial bowel resectio | Phase 3 | Failed to meet primary and secondary endpoints | 03/13/2012 |
| TZYM | 3.00 | Ulimorelin ULISES 008 | To accelerate GI recovery in subjects who have undergone partial bowel resectio | Phase 3 | Data from second Phase 3 trial due by end of June 2012 | 05/11/2012 |
| TZYM | 3.00 | TZP-102 | Diabetic gastroparesis | Phase 2b | Phase 2b data due by end of 2012 | 05/11/2012 |
| VICL | 2.84 | Temusi | Ischemia | Phase 3 | Endpoint not met | 11/20/2010 |
| VICL | 2.84 | TransVax(TM) vaccine | Hematopoietic cell transplant | Phase 3 | Initiate Phase 3 2H 2012 | 05/04/2012 |
| VICL | 2.84 | TransVax(TM) vaccine | solid organ transplant (SOT) | Phase 2 | Initiate Phase 2 2H 2012 or shortly after | 05/04/2012 |
| VICL | 2.84 | Collategene | Peripheral arterial disease | Phase 2 | Initiate Phase 3 2012 | 11/02/2011 |
| VICL | 2.84 | Allovectin-7 | Cancer - melanoma | Phase 3 | Topline data late 2012 | 05/04/2012 |
| VNDA | 4.02 | Tasimelteon | Insomnia | Phase 3 | Data end 2012, poss NDA filing mid- 2013 | 05/09/2012 |
| VNDA | 4.02 | Tasimelteon | Depression | Phase 2b | Phase 2b/3 trial initiated Sept 2011. Data due 1H 2013 | 05/09/2012 |
| VNDA | 4.02 | Fanapt (Injectable) | Schizophrenia | Phase 2 | MAA filed July 2011, expects to respond to 120day questions by mid May 2012 | 02/15/2012 |
| VPHM | 19.24 | Subcutaneous Delivery of Cinryze with Hyaluronidase | Hereditary angioedema | Phase 2 | Phase 2 initiated Sept 2011, prelim data released Dec 2011 | 12/06/2011 |
| VPHM | 19.24 | VP 20621 | C. difficile infection (CDI) | Phase 2 | Phase 2 initiated May 2011 | 09/01/2011 |
| VPHM | 19.24 | Buccolam | Pediatric epilepsy | MAA | CHMP issued positive opinion June 2011 | 09/01/2011 |
| VTUS | 10.50 | VEN 307 (diltiazem cream) | Anal fissures | Phase 3 | Phase 3 positive data released May 2012. Phase 3 US trial to be initiated 2H 2012 | 05/15/2012 |
| VTUS | 10.50 | VEN 308 (phenylephrin) | Fecal incontinence | Phase 2 | Does not expect to further development in short term | 12/20/2011 |
| VTUS | 10.50 | VEN 309 (iferanserin) | Symptomatic hemorrhoids | Phase 3 | First of two Phase 3 trials initiated Aug 2011. Data due late June, early July 2012. | 05/10/2012 |
| VVUS | 22.40 | Qnexa | Obesity | PDUFA | PDUFA Apr 17 2011. Advisory Committee Meeting Feb 22 2012 voted 20-2 in favour | 02/23/2012 |
| VVUS | 22.40 | Avanafil | Erectile dysfunction | Approved | Approved April 27 2012 | 04/27/2012 |
| VVUS | 22.40 | Qnexa | Obstructive sleep apnea | Phase 2 | Completed | 08/08/2010 |
| XNPT | 5.83 | Arbaclofen placarbil | Spasticity in multiple sclerosis (MS) | Phase 3 | Initiated under SPA, topline data due near end of 2012 | 02/15/2012 |
| XNPT | 5.83 | Arbaclofen placarbil | GERD | Phase 2b | FAIL - endpoints not met Mar 2011 | 03/22/2011 |
| XNPT | 5.83 | Horizant | Restless Legs | Approved | FDA Approved Apr 6 2011 | 04/07/2011 |
| XNPT | 5.83 | Horizant | Postherpetic Neuralgia | PDUFA | PDUFA June 9 2012 | 11/05/2011 |
| XNPT | 5.83 | XP21279 | Parkinson's Disease | Phase 2b | Data released Dec 2011, no statistical improvement over Sinemet | 12/06/2011 |
| XNPT | 5.83 | Horizant | Migraine | Phase 2b | Failed | 07/07/2010 |
| XOMA | 2.37 | XOMA 052 | Diabetes | Phase 2b | Data released Mar 22, 2011. Endpoint not met | 12/22/2011 |
| XOMA | 2.37 | XOMA 052 | Diabetes | Phase 2a | Prelim data released Jan '10, full data released 2Q 2011 | 06/09/2011 |
| XOMA | 2.37 | XOMA 052 Gevokizumab | Behcet's uveitis | Phase 3 | Initiate 2Q 2012 | 03/15/2012 |
| XOMA | 2.37 | XOMA 052 Gevokizumab | Moderate to Severe Acne Vulgaris | Phase 2 | Initiated Phase 2 Dec 2011. Data due 2012 | 03/15/2012 |
| XOMA | 2.37 | XOMA 052 Gevokizumab | Cardiovascular disease | Phase 2 | Initiate Phase 2 during 2012 | 04/08/2012 |
| YMI | 1.97 | CYT387 | Myelofibrosis | Phase 2 | Phase 3 planned 3Q 2012. Final data of Phase 1/2 Core trial due by end 2012. Interim data from Phase 1/2 Extension trial due by end of 2012. Interim data from the BID (twice-daily dosing) Phase 2 trial also due by end of 2012. | 05/12/2012 |
| YMI | 1.97 | CYT997 | Cancer - Glioma | Phase 1/2 | Prelim data expected 1H 2011 | 09/23/2011 |
| YMI | 1.97 | Nimotuzmab | Cancer - NSCLC | Phase 2 | Discontinued | 09/18/2011 |
| YMI | 1.97 | Nimotuzmab | Cancer - pancreatic | Phase 2b/3 | Enrolment ongoing | 09/23/2011 |
| YMI | 1.97 | Nimotuzmab | Cancer - Glioma (adult) | Phase 3 | Phase 3 efficacy data due 2H 2011 | 09/23/2011 |
| YMI | 1.97 | Nimotuzmab | Cancer - Gastric | Phase 2 | Data released Jan 2011 | 01/21/2011 |
| YMI | 1.97 | Nimotuzmab | Diffuse intrinsic pontine glioma (DIPG) | Phase 2 | Prelim Data released Oct 2011 | 10/31/2011 |
| ZGNX | 1.79 | ZX002 | Moderate to severe pain | Phase 3 | NDA filed May 2 2012 | 05/04/2012 |
| ZIOP | 4.44 | Darinaparsin | Cancer - Myeloma | Phase 2 | Complete | 07/30/2010 |
| ZIOP | 4.44 | IL12 DNA | Cancer | Phase 2 | Initiate Phase 2 2H 2012 | 03/01/2012 |
| ZIOP | 4.44 | Palifosfamide | Cancer - sarcoma | Phase 3 | Data due 2H 2012 | 05/04/2012 |
| ZIOP | 4.44 | Palifosfamide | Cancer - small cell lung SCLC | Phase 3 | Plan to initiate Phase 3 early 3Q 2012 | 05/04/2012 |
| ZLCS | 0.77 | Synavive | Rheumatoid arthritis | Phase 2b | Initiated June 2011, enrolment completed Apr 2012, topline data due 3Q 2012 | 05/01/2012 |
| ZLCS | 0.77 | Z160 | Neuropathic pain | Phase 2 | Initiate Phase 2 during 2H 2012 | 03/08/2012 |
Check dates for RIGL, they entered in a reverse order (07/03/2012, instead of 03/07/2012).
Thanks for that! I live in New Zealand so am used to having the date like 28/03/12 so unfortunately I’m always prone to making that error. Error has been fixed. Thanks!